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Abstract 
PHLPP2, a member of the PHLPP phosphatase family, which targets oncogenic kinases, 
has been actively investigated as a tumor suppressor in solid tumors. Little was known, 
however, regarding its regulation and function in hematological malignancies. The first half 
of this dissertation describes a novel miR-17~92-based mechanism for repression of 
PHLPP2 protein expression in late differentiation stage acute myeloid leukemia (AML) 
subtypes. ATRA (all-trans retinoic acid), a drug used for terminally differentiating AML 
subtypes, was able to induce PHLPP2 protein levels and phosphatase activity significantly 
by suppressing miR-17-92 expression. The effect of ATRA on miR-17~92 expression was 
mediated through its target, transcription factor C/EBP, which interacts with the intronic 
promoter of the miR-17~92 gene cluster to inhibit its transactivation. The second half of 
this dissertation provides evidence for a novel metabolic function for PHLPP2 and 
describes the first identification of the energy sensing kinase, AMPK, as a unique PHLPP2 
substrate. PHLPP2 could dephosphorylate phospho-AMPK (T172) both intracellularly and 
in vitro.  PHLPP2 silencing protected Jurkat T-ALL cells from an apoptotic response to low 
glucose-induced metabolic stress through activation of AMPK signaling. The pro-survival 
effect of PHLPP2 knockdown under metabolic stress is likely mediated through AMPK-
activated fatty acid oxidation. PHLPP2 regulates AMPK phosphorylation in a variety of 
tumor types and is the first specific AMPK phosphatase to be identified. These studies on 
PHLPP2 expression and function expand current knowledge and understanding of the 
role of PHLPP phosphatases in cancer, and particularly in leukemia. In light of the pivotal 
role played by AMPK in a number of metabolic diseases, the PHLPP2/AMPK axis is also 
expected to provide new insights into therapies targeting these diseases.  
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Protein phosphorylation: kinases and phosphatases 
Protein phosphorylation is a modification of fundamental importance in biological systems 
and dynamic phosphorylation by kinases and dephosphorylation by phosphatases are 
major molecular mechanisms for regulating protein function and cell fate in response to 
extracellular and intracellular stimuli [Hunter, 1995]. In mammals, aberrant activation or 
inactivation of kinases/phosphatases is often associated with disease occurrence, and 
particularly with tumorigenesis and tumor progression. A large majority of anti-cancer 
drugs target these abnormal kinases/phosphatases to inhibit tumor cell proliferation or 
induce tumor cell death [Zhang et al., 2009; McConnell and Wadzinski, 2009]. A number 
of new kinases and phosphatases have been discovered in the past two decades; a 
comprehensive understanding of the expression, regulation and function of these key 
kinases/phosphatases will provide new insights into signaling pathways within tumor cells 
and on this basis, lead to novel anti-cancer therapeutics.  
PHLPP phosphatase family 
The PHLPP (PH domain Leucine rich repeat Protein Phosphatase) serine/threonine 
phosphatases belong to the metal dependent protein phosphatase (PPM) family, which 
requires magnesium or manganese for phosphatase activity and is insensitive to 
phosphatase inhibitor okadaic acid [Warfel and Newton, 2012]. The PHLPP subfamily 
comprises two members: PHLPP1 and PHLPP2 (PHLPPL), coded by phlpp1 gene located 
on chromosome18 and phlpp2 gene on chromosome16, respectively [Gao et al., 2005; 
Brognard et al., 2007]. PHLPP1 has two splicing variants: PHLPP1α and PHLPP1β. As 
shown in Figure 1-1, all three PHLPP proteins share a PH (Pleckstrin Homology) domain, 
a LRR (Leucine Rich Repeat) domain, a PP2C catalytic phosphatase domain, and a PDZ 
binding motif at the C terminus. Both PHLPP1β and PHLPP2 have an additional RA (Ras 
Association) domain. These regulatory domains influence PHLPP phosphatase activity 
towards their targets [Gao et al., 2005; Brognard and Newton, 2008].  
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Figure 1-1. The protein structure of PHLPP phosphatase family. PHLPP phosphatase family 
include three members: PHLPP1α and PHLPP1β two splicing isoforms and PHLPP2. Both 
PHLPP1β and PHLPP2 have a Ras-Association domain (RA), a Pleckstrin Homology domain (PH), 
a Leucine Rich Repeats domain (LRR), a PP2C phosphatase domain (PP2C) and PDZ-ligand at 
the C-terminus. PHLPP1α lacks the RA domain at the N-terminus. 
Since the discovery of PHLPP1 as an AKT phosphatase in 2005 and PHLPP2 in 2007 
[Gao et al., 2005; Brognard et al., 2007], four direct targets of PHLPP phosphatases - AKT, 
PKC, P70S6K and MST1- have been identified. All four are key kinases in cell survival or 
apoptosis pathways [Gao et al., 2005; Gao et al., 2008; Liu et al., 2011; Qiao et al., 2010]. 
PHLPPs dephosphorylate AKT at Ser473, a critical phosphorylation site, inactivating AKT, 
which results in attenuation of the amplitude of AKT-mTOR signaling pathway to inhibit 
cell proliferation [Gao et al., 2005]. Interestingly, PHLPP family members show specificity 
towards AKT isoforms - PHLPP1 is specific to AKT2 and AKT3, while PHLPP2 is specific 
to AKT1 and AKT3. This allows PHLPP isoforms to differentially terminate AKT signaling; 
for example, PHLPP1 regulates AKT2-HDM2 while PHLPP2 controls the activation of the 
AKT3-p27 pathway [Gao et al., 2005; Brognard et al., 2007]. Unlike PHLPP 
dephosphorylation of AKT, which regulates its kinase activity, the dephosphorylation of 
PKC at the hydrophobic motif by PHLPP phosphatases promotes its degradation, which 
inhibits cell survival [Gao et al., 2008]. P70S6K is also dephosphorylated by PHLPP at a 
hydrophobic motif (Thr389). Phosphorylated S6K binds to the translation initiation complex 
and induce translation process, so its dephosphorylation by PHLPP leads to decreased 
protein translation and reduced cell size [Liu et al., 2011]. When MST1, a pro-apoptotic 
kinase, is dephosphorylated by PHLPP at Thr387, it becomes activated and promotes 
apoptosis [Qiao et al., 2010].  
Thus, PHLPP phosphatases control the amplitude of several signaling pathways to 
regulate cell proliferation and apoptosis by regulating the activity and/or stability of their 
targets. Consistent with its potential tumor suppressor function, PHLPP gene expression 
level is repressed in various tumors. For example, the expression of PHLPP1 or PHLPP2 
is either lost or reduced in 78% and 86% of colon tumor tissues [Gao et al., 2005]. Levels 
of PHLPP proteins were greatly reduced in human pancreatic ductal adenocarcinoma [Lu 
et al., 2005]. PHLPP expression was found to be dramatically downregulated in tissue 
microarrays of breast cancer, pancreas cancer and GI tract tumor tissues [Qiao et al., 
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2010]. Moreover overexpression of PHLPP has been shown to inhibit tumorigenesis in 
several xenograft mouse models [O’Neill et al., 2013].    
PHLPP phosphatases have been studied at the molecular and cellular level and in in vivo 
mouse models. However, all of the studies directed at understanding its regulation and 
expression had been focused on solid tumors, and the understanding of its function been 
limited to the dephosphorylation of the four known targets and their control of cell 
proliferation and apoptosis [Warfel and Newton, 2012]. I have focused my dissertation 
research on the regulation and function of PHLPP2 in hematological malignancies 
(leukemias) and describe the results of my investigations in the following chapters.  
Leukemia 
Leukemia is a malignant progressive disease in which the bone marrow and other blood-
forming organs produce increased numbers of immature or abnormal leukocytes. These 
suppress the production of normal blood cells, leading to anemia and other pathological 
conditions. Leukemia can be of the ‘acute’ variety where most of the abnormal cells are 
immature and the disease progresses rapidly, or ‘chronic’, where the abnormal cells 
mature partly but not completely [Redaelli et al., 2003].  Disease progression in chronic 
leukemia can take a long time before they cause problem. Leukemia can also be 
subdivided to two groups: myeloid leukemia and lymphocytic (or lymphoid) leukemia, 
based on the lineage of bone marrow cells that are affected. There are totally four major 
types of leukemia: acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute 
lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL).   
Acute Myeloid Leukemia (AML) 
AML is the most severe among the four major types of leukemia, with the lowest 5-year 
survival rate (26.6 percent in 2016). The two most commonly used classification systems 
for AML are French-American-British (FAB) system and the World Health Organization 
(WHO) system. The FAB system divides AML to eight subtypes, M0 to M7, according to 
the type of cells from which the leukemia develops, their maturity and differentiation levels 
[Lowenberg et al., 1999]. In general, the more mature or differentiated the AML cell, the 
later the subtype in the FAB system. The M3 AML subtype is also known as acute 
promyelocytic leukemia (APL) which typically harbors the t(15:17)(q22:q12) translocation 
cytogenic signature and is classified as “AML with recurrent genetic abnormalities” in the 
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WHO classification system. Although treatment of AML is largely limited to traditional 
chemotherapy and bone marrow transplant, APL patients are treated and often cured with 
the drug All-Trans-Retinoic-Acid (ATRA). ATRA binds to its nuclear receptor Retinoid Acid 
Receptor α (RARα) which acts as a transcription factor regulating the expression of the 
downstream target, such as C/EBPβ, and induces the ‘terminal’ differentiation of these 
leukemia cells [Duprez et al., 2003; Huber et al., 2012]. In the APL cells, ATRA also 
induces the degradation of the oncogenic fusion protein PML/RARα generated from the 
genetic translocation of t(15:17)(q22:q12), eventually leading cell death [Takitani et al., 
2003; Zhang et al., 2000]. The FAB classification system is far from ideal – FAB AML 
subtypes have varying prognoses and responses to therapy and biomarkers for the 
different FAB subtypes are still not well categorized. Identifying key regulators of cell 
differentiation/death will help reveal new biomarkers for the different AML subtypes to 
facilitate diagnosis and novel anti-cancer therapeutics.  
Regulation of PHLPP expression 
PHLPP protein expression and activity is suppressed through various mechanisms in 
cancers. While most studies on PHLPP2 have focused on genetic alterations in solid 
tumors [O’Neill et al., 2013], PHLPP2 protein expression in small cell lung and colorectal 
cancers is also restricted through translational suppression [Liu et al., 2011] and post-
transcriptional control by microRNAs, such as miR-205 and miR-224 [Cai et al., 2013; Liao 
et al., 2013]. MicroRNAs (miRNA or miR) are 20~24 nucleotide non-coding RNAs that are 
derived from hairpin precursors. Mature miRNAs bind to the complementary binding sites 
in the 3’-Un-Translated Region (3’UTR) of the target mRNAs and suppress gene 
expression by inhibiting mRNA translation and/or inducing mRNA degradation.  
The PHLPP2 3’UTR harbors complementary binding sites for a subset of microRNAs 
belonging to the miRNA-17~92 cluster [Rao et al., 2012]. This cluster comprises six 
miRNAs on chromosome 13, transcribed as a single polycistronic unit [He et al., 2005; 
Olive et al., 2013]. Also known as oncomir-1, the cluster enhances cell proliferation or 
inhibits apoptosis by suppressing targets such as Bim, E2F1 and PTEN and is markedly 
overexpressed in human cancers [Inomata et al., 2009; Hayashita et al., 2005; Lu et al., 
2005; Mogilyansky et al., 2013; Nagel et al., 2009; Tagawa and Seto, 2005; Wang et al., 
2013].  Reduced levels of PHLPP2 in chemo-resistant miR-17~92 overexpressing mantle 
cell lymphomas had suggested that the phosphatase could be a target of oncomir-1 [Rao 
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et al., 2012]. Known major activators of the miR-17~92 cluster are transcription factor c-
MYC and members of the E2F family, while p53 acts as a repressor under hypoxic 
conditions [O’Donnel et al., 2005; Sylvestre et al., 2007; Woods et al., 2007; Yan et al., 
2009]. 
Since PHLPP2 phosphatases are potential therapeutic targets, it is important to 
understand mechanisms that regulate PHLPP2 protein expression. As mentioned earlier, 
most recent investigations of this tumor suppressor family have focused primarily on its 
regulation in solid tumors and their derivative cell lines, rather than in hematological 
malignancies. The importance of both PHLPP2 and the miR-17~92 cluster in cell 
survival/apoptosis signaling prompted our investigation of their coordinate regulation in 
leukemia. The studies described in Chapters 2 and 3 reveal direct control of PHLPP2 
expression through its 3’UTR by the miR-17~92 miRNAs in acute myeloid leukemia (AML) 
subtypes, and a negative correlation between PHLPP2 protein and miR-17~92 cluster 
levels in these cancers. These studies also identify a novel pathway for up-regulation of 
the phosphatase through repression of the oncomir-1 cluster by C/EBP, an ATRA-
induced transcription factor.  
Role for PHLPP2 in metabolism of cancer cells  
Previous studies of PHLPP function had centered on its tumor-suppressor role of either 
inhibiting cell proliferation, or inducing cell apoptosis in solid tumors, via its regulation of 
four known targets [O’Neill et al., 2013]. There has been as yet no direct association with 
cancer metabolism as part of PHLPP’s tumor suppressor role. The Warburg effect - 
preferential conversion of glucose to lactate even in the presence of oxygen - also known 
as aerobic glycolysis, is recognized as one of the hallmarks of cancer [Vander Heiden et 
al., 2009]. Under these conditions, fuel sources other than glucose are relied upon to 
satisfy the increased metabolic needs of cancer cells, in terms of energy production, 
biomass generation and redox homeostasis [Vander Heiden and DeBerardinis, 2017]. 
Glutamine, acetate, fatty acids, branched chain amino acids are often key supplemental 
nutrients that allow cancer cells to reprogram their metabolism to survive and proliferate 
rapidly [DeBerardinis and Chandel, 2016; White 2013]. Purification and mass 
spectrometric analysis had identified PHLPP2 as a component of a glucose sensitive 
multi-protein complex in the cytosol of Jurkat T-ALL cells [Lowman et al, 2012 and data 
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not shown]. This suggested to us that PHLPP2 activity could potentially regulate the 
response to metabolic stress in the leukemia cells.  
AMPK- key energy sensor 
Preliminary targeted metabolomics using 13C labelled glucose, carried out to determine 
whether PHLPP2 affected how the cells utilized glucose (described in Chapter 4), did not 
reveal much difference in the pathways or glycolytic intermediates between control cells 
and cells lacking PHLPP2. However, a significant increase in the intracellular AMP/ATP 
and ADT/ATP ratios in the absence of PHLPP2, suggested it could be involved in the 
response to metabolic stress in the Jurkat cells.  The AMP/ATP ratio is a prime indicator 
of the energy status and is sensed by AMPK. AMPK (5’-AMP activated protein kinase) is 
the key energy sensor that regulate cellular energy homeostasis [Carling et al., 2011]. 
AMPK is a heterotrimer that is composed by three subunits: AMPKα (AMPKα1 and 
AMPKα2) catalytic subunit and AMPKβ (AMPKβ1, AMPKβ2), AMPKγ (AMPKγ1, AMPKγ2 
and AMPK γ3) regulatory subunits [Carling et al., 2012].  When the AMP/ATP or ADP/ATP 
ratio increases in cells that are under metabolic stress, such as nutrient/ cytokine 
deprivation or hypoxia, AMP competes with ATP to bind the AMPKγ subunit. The 
interaction with AMP causes a conformational change in the AMPKγ subunit, which 
exposes the phosphorylation site at Threonine 172 (Thr172) on the AMPKα subunit (Thr183 
on AMPKα1 and Thr172 on AMPKα2) [Hawley et al, 1996]. Phosphorylation of AMPKα at 
Thr172 activates it to phosphorylate its downstream targets, such as Acetyl-CoA 
Carboxylase (ACC), ULK1 and TSC2 [Mack et al., 2012; Inoki et al., 2003]. This turns on 
catabolic pathways such as fatty acid oxidation and autophagy, while switching off 
anabolic pathways such as fatty acid synthesis and protein synthesis, resulting in an 
increase in ATP production and a decrease in its consumption, which balances the 
AMP/ATP ratio and restores energy homeostasis in the cells (see model in Figure 1-2) 
[Kim and He, 2013]. 
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Figure 1-2. Upstream regulation of AMPK and metabolic consequences of AMPK activation. 
AMPK is a ‘master regulator’ of cell metabolism. Its downstream target, ULK1, a key 
inducer of autophagy, is activated via phosphorylation by AMPK at Ser555 [Egan et al., 
2011; Kim et al., 2011; Mack et al., 2012]. Acetyl-CoA Carboxylase (ACC), another pivotal 
target of AMPK and a regulator of fatty acid metabolism, is the enzyme that catalyzes the 
irreversible carboxylation of acetyl-CoA to produce malonyl-CoA [Fullerton et al., 2013]. 
There are two isoforms of ACC: ACC1 and ACC2, both of which can be phosphorylated, 
yet inhibited by AMPK. The malonyl-CoA generated by ACC1 in the cytosol is utilized for 
fatty acid biosynthesis, whereas the malonyl-CoA produced by ACC2 in the outer-
membrane of mitochondrial inhibits carnitine palmitoyl transferase 1 (CPT1) and, in turn, 
fatty acid β-oxidation [Wakil and Abu-Elheiga, 2009]. Thus, by phosphorylating and 
inhibiting both ACC1 and ACC2, activated AMPK represses fatty acid synthesis while 
promoting fatty acid oxidation [Fullerton et al., 2013]. AMPK also regulates mTOR-
dependent protein synthesis. TSC2, the negative regulator of mTOR activity, is 
phosphorylated and activated by AMPK [Inoki et al., 2003]. The adapter protein of mTOR1, 
Raptor, is phosphorylated but inhibited by AMPK [Gwinn et al., 2008].  Besides autophagy, 
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fatty acid metabolism and protein synthesis, other metabolic pathways such as glycolysis 
and sterol synthesis are also regulated by AMPK through its downstream targets TXNIP, 
HMGCR [Wu et al., 2013; Sato et al., 1993].   
AMPK activity is regulated by the level of phosphorylation of Thr172 on the AMPKα subunit 
[Willows et al., 2017].  Thus, the AMPK kinase/ AMPK phosphatase axis is important for 
controlling AMPK activation and function and for terminating AMPK signaling pathways. 
Upstream kinases of AMPK, the LKB1/STRAD/MO25 complex [Hawley et al., 2003; Shaw 
et al., 2004; Woods et al., 2003] and Ca2+-dependent CaMKKβ kinase, have been well 
described [Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005]. However, a 
phosphatase of AMPK has yet to be identified, although previous studies had shown that 
PP2C family phosphatases could dephosphorylate AMPKα in vitro [Stephen et al., 1995; 
Stein et al., 2000].  We hypothesize that PHLPP2 as a member of the PP2C phosphatase 
family, functions as an AMPK phosphatase.  
The research results described in Chapter 4 and 5 together identify PHLPP2 as a potential 
regulator of the cellular response to metabolic stress via phosphorylation (and activation) 
of AMPK. The data also suggest that PHLPP2 regulates fatty acid oxidation and, thus, the 
utilization of fatty acid to fuel energy production, through an AMPK-ACC route when 
glucose supply is limited. Thus, our studies not only reveal a new target, they also reveal 
a novel metabolic function, for the PHLPP2 phosphatase. This would also be the first 
identification of a specific phosphatase of AMPK. Overall, the research described in these 
chapters will provide new insights into the regulation of the key energy sensor AMPK, not 
only in cancer cells, but also in metabolic diseases.  
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Chapter 2 
PHLPP2 is post-transcriptionally regulated by 
microRNA-17~92 cluster in AML cells 
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Introduction 
The PH-domain Leucine Rich Repeat Protein Phosphatase2, PHLPP2 is a member of the 
PHLPP family serine-threonine phosphatases that are emerging as central players in cell 
survival and death regulation [Gao et al., 2005; Warfel and Newton, 2012]. To date four 
PHLPP substrates, Akt, PKC, Mst1 and S6K1, all kinases involved in cell survival or 
apoptosis, have been identified [Brognard and Newton, 2008; Brognard et al., 2007; Liu 
et al., 2011; Qian et al., 2010]. Dephosphorylation inactivates Akt, S6K1 and PKC, and 
subsequently cell survival signaling, whereas dephosphorylation of Mst1 activates its 
apoptotic function.  
PHLPP protein expression and activity is suppressed through various mechanisms in 
cancers. While most studies on PHLPP2 have focused on genetic alterations in solid 
tumors [O’Neill et al., 2013], PHLPP2 protein expression in small cell lung and colorectal 
cancers is also restricted through translational suppression [Liu et al., 2011] and post-
transcriptional control by microRNAs, miR-205 and miR-224 [Cai et al., 2013; Liao et al., 
2013]. The PHLPP2 3’UTR harbors complementary binding sites for a subset of 
microRNAs belonging to the miRNA-17~92 cluster [Rao et al., 2012]. This cluster 
comprises six miRNAs on chromosome 13, transcribed as a single polycistronic unit [He 
et al., 2005; Olive et al., 2013]. Also known as oncomir-1, the cluster enhances cell 
proliferation or inhibits apoptosis by suppressing targets such as Bim, E2F1 and PTEN 
and is markedly overexpressed in human cancers [Inomata et al., 2009; Hayashita et al., 
2005; Lu et al., 2005; Mogilyanshky et al., 2013; Nagel et al., 2009; Tagawa et al., 2005; 
Wang et al., 2013]. Reduced levels of PHLPP2 in chemo-resistant miR-17~92 
overexpressing mantle cell lymphomas had suggested that the phosphatase could be a 
target of oncomir-1 [Rao et al., 2012]. 
Since PHLPP2 phosphatases are potential therapeutic targets, we were interested in 
understanding mechanisms that regulate PHLPP2 protein expression. Most recent 
investigations of this tumor suppressor family have focused primarily on its regulation in 
solid tumors and their derivative cell lines, rather than in hematological malignancies. The 
importance of both PHLPP2 and the miR-17~92 cluster in cell survival/apoptosis signaling 
prompted my investigation of their coordinate regulation in leukemia. 
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Results 
PHLPP2 protein is poorly expressed or absent in specific AML subtypes 
We compared PHLPP2 protein levels in a variety of human myeloid and lymphoid 
leukemia cell lines with those in cell lines derived from solid tumors (Figure 2-1A). Western 
blots revealed a range of expression, with immortalized B cells (B-NB) showing the highest 
levels. In three AML cell lines, THP-1, HL-60 and U937, PHLPP2 protein levels were 
greatly reduced or absent (Figure 2-1A). Under the FAB classification system there are 8 
AML subtypes, M0 to M7, classified by myeloid lineage and degree of differentiation of the 
leukemia cells [Lowenberg et al., 1999]. THP-1 and U-937 are M5 subtypes, while HL-60 
is classified as an M3 AML (promyelocytic leukemia) and, more recently, as an M4 AML 
(myelomonocytic) subtype. Figure 2-1B shows that the PHLPP2 protein was suppressed 
in the more differentiated (M3/M4 and M5) AML while levels in M0 and M2 lines were 
comparable to those in K562, a chronic myeloid leukemia (CML) and Jurkat, a T cell acute 
lymphocytic leukemia (T-ALL). These observations were further supported by PHLPP2 
Western blots of patient cells of M0, M1 and M4 AML subtype (Figure 2-1C).  
 
Figure 2-1. PHLPP2 protein is poorly expressed or absent in specific AML subtypes. A. 
Western Blot (WB) showing PHLPP2 and β-Actin expression in a variety of established 
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hematopoietic and epithelial cell lines (all human except for HC-11). From left to right: B-NB (Normal 
B cells), HL-60 (AML), Jurkat (T-ALL), K562 (CML), Molt-4 (T-ALL), THP-1 (AML), U937 (AML); 
HEK-293 (Human Embryonic Kidney cells), A549 (lung cancer), C4-2 (prostate cancer), DLD-1 
(colorectal cancer), HC-11 (mouse mammary epithelial cells), HeLa (cervical cancer), LnCAP 
(prostate cancer) and MCF-7 (breast cancer). B. WB of established AML cell lines (sorted by FAB 
classification) from L to R: KG-1 (M0), Kasumi-1 (M2), HL-60 (M3), MV4-11 (M5), THP-1 (M5) and 
U937 (M5). C. WB of AML patient samples (sorted by FAB classification) from L to R: “00,21” (M0), 
“02,11” (M1), “01,01” (M4), “03,06” (M5).  
PHLPP2 mRNA is expressed at similar levels in AML 
Since PHLPP2 is deleted or mutated at a high frequency in solid tumors [O’Neill et al., 
2013] we checked the TCGA database [Cerami et al., 2012; Gao et al., 2013] to determine 
whether the poor expression of PHLPP2 in AML was also due to gene mutation or deletion. 
Our analysis revealed that, compared with breast and prostate tumors, the PHLPP2 gene 
was rarely altered in AML, with no mutations and a deletion rate of < 3% (Figure 2-2A). 
Moreover, there was only one deep deletion and eight instances of upregulated transcripts 
in a total of 166 AML patient samples in the database (Figure 2-2B), suggesting that gene 
alteration was unlikely to account for poor expression of PHLPP2 proteins in these cancers. 
We checked whether the observed low PHLPP2 protein expression correlated with 
PHLPP2 mRNA levels with primer pairs that amplified different regions of the 3.9 kilobase 
PHLPP2 transcript (Figure 2-2C). PHLPP2 mRNA was detected by Q-PCR using either 
the 5’ LRR primer or 3’ PDZ-ligand sets (Figure 2-2D) in all the AML lines.  mRNA levels 
in the M5 lines, where PHLPP2 protein levels ranged from low to absent (Figure 2-2B), 
were comparable to those in high PHLPP2 protein-expressing K562 or Jurkat cells (Figure 
2-1B). Notably, PHLPP2 mRNA levels in three AML patient samples tested, 00,21 (M0 
with detectable PHLPP2 protein, Figure 2-1C), and 01,01 or 03,06 (M4 with lower PHLPP2 
protein, Figure 2-1C), were also comparable (Figure 2-2E).  
The half-life of PHLPP2 transcripts was similar in both high and low expressing leukemia 
cell lines (Figure 2-3A), ruling out mRNA degradation as the reason for suppression of 
PHLPP2 protein in specific AML subtypes.  We also treated HL-60 and U937 cells with 
MG132 and bortezomib (BTZ) to check for increased proteasomal degradation of PHLPP2 
protein, as reported previously [Li et al., 2013]. Neither proteasome inhibitor increased 
PHLPP2 protein expression in the AML cell lines (Figure 2-3B). Thus, these data point to 
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a significant reduction in PHLPP2 protein levels in specific AML subtypes (M3-M5) via a 
post-transcriptional mechanism.  
 
Figure 2-2. PHLPP2 mRNA is expressed at similar levels in AML. A. Schematic of TCGA data 
(cBioPortal analysis of 106 studies) demonstrating alteration in the PHLPP2 gene across cancers. 
B. TCGA data for PHLPP2 mRNA expression in 166 AML patient samples with 1 deep deletion 
and 8 instances of mRNA regulations. C. The PHLPP2 protein domains (not to scale) and locations 
of PCR primers. Orange primers amplified a region in the LRR domain; blue primers amplified a 
region within the PDZ-binding motif at the 3’ end. D. PHLPP2 mRNA levels were analyzed by real-
time PCR (R-PCR) using the PDZ primers as shown in D. PHLPP2 mRNA levels in each of the cell 
lines shown were normalized to those in Jurkat cells. E. PHLPP2 mRNA levels in representative 
AML patient samples, 00,21 (M0), 01,01 (M4) and 03,06 (M4), were detected by RT-PCR. PHLPP2 
mRNA levels in 01,01 and 03,06 were normalized to those in 00,21.  
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Figure 2-3. the absence of PHLPP2 protein in specific AML subtypes is not due to mRNA 
degradation or protein degradation. A. PHLPP2 mRNA half-life is comparable in Jurkat and 
U937 cells. The cells were treated with Actinomycin D (Act D) for 1 hour and 4 hours. At each time 
point, mRNA were extracted from the cell lysates and LRR primers were used to amplify PHLPP2 
mRNA. B. The presence of PHLPP2 protein in specific AML subtypes is not due to protein 
degradation. HL-60 or U937 cells were treated with MG132 (5 or 10 μM) or BTZ (50 or 100 nM) for 
6 hours. Then the cells were collected and WB was performed to detect the protein levels of 
PHLPP2, Noxa and β-Actin. 
The low PHLPP2 protein levels are correlated with high miR-17~92 cluster levels in 
specific AML subtypes 
We investigated the possibility that miR-17~92 was regulating translation of the PHLPP2 
messenger in AML. The PHLPP2 3’UTR harbors complementary binding sites for a subset 
of microRNAs, miR-17, 19, 18a, 20a and 92a, of the miRNA-17~92 cluster (Figure 2-4). 
PHLPP2 was previously shown to be responsive to miR-17~92 miRNAs in transfected 
HEK 293 cells [Rao et al., 2011]. Our data showed clear negative correlation between 
PHLPP2 protein levels and miRNA-17~92 levels in AML cell lines and patient samples.  
Three M5 cell lines with reduced PHLPP2 protein had higher levels of miR-17~92 
transcripts than Jurkat cells (Figure 2-5A). Additionally, levels of all individual miR-17~92 
miRNAs in M4 patient cells were higher than those in an M0 patient sample (Figure 2-5B).  
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Figure 2-4. PHLPP2 3’UTR (3939 bp) possesses binding sites for miRNAs from the miR-
17~92 . Each specific sequence that binds to the miRNA seed sequence within these sites is shown 
in bold. The mutations for each binding site (three-nucleotide mutation) are shown in underlined 
italics.  
 
Figure 2-5. the PHLPP2 protein levels are correlated with high miR-17~92 cluster levels in 
specific AML subtypes. A. Expression of miRNAs, miR-17, -18a, -20a, -92, and -19b, from the 
miR-17~92 cluster was quantified in the indicated cell lines using the miR-17~92 plate assay kit 
(Signosis). Values were normalized to internal control, U6, in each cell line. n.s represents no 
significant difference; * p<0.05; ** p<0.01; *** p<0.001. B. miR-17~92 cluster levels were quantified 
in the indicated M0 and M4 AML subtype patient samples using the Signosis plate assay.  
PHLPP2 protein expression is de-repressed by an shRNA of miR-17~92 
To confirm that miRNA-17~92 transcripts were key regulators of PHLPP2 mRNA in AML, 
we checked the ability of a tetracycline-inducible construct, expressing three shRNAs 
against the primary miR-17~92 cluster transcript, to induce expression of PHLPP2 and of 
known miRNA-17~92 target, Bcl-2 protein Bim [Inomata et al., 2009]. Levels of both 
proteins were increased in cells transfected with the shRNA (Figure 2-6A), and these were 
further upregulated by increasing concentrations of doxycycline (Dox) in HEK 293 cells. 
The inhibitor construct also enhanced Bim and PHLPP2 protein expression in HL-60 and 
U937 cells (Figure 2-6B). Thus, inhibition of miR-17~92 in AML cells could reverse the 
suppression of PHLPP2 translation. Attempts to further increase expression with Dox 
treatment resulted in rapid apoptosis of the AML transfectants (not shown), suggesting 
these cells were sensitive to increased levels of miR-17~92 targets.  
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Figure 2-6. PHLPP2 protein expression is de-repressed by an shRNA of miR-17~92 in AML. 
A. WBs of lysates from HEK-293 cells transfected with 2 μg TripZ-shRNA-miRNA-17~92 (sh-miR-
17~92) or empty vector (EV), treated with 1 μg/ml Doxycycline (Dox) for EV or 0.3 μg/ml, 1 μg/ml, 
3 μg/ml Dox for sh-miR-17~92 24 hours post-transfection and harvested 48 hours later. B. WBs of 
lysates prepared from HL-60 or U937 cells transfected with 3 μg TripZ-empty vector (EV) or TripZ-
shRNA-miRNA 17-92 (shRNA). Viable cells were purified by gradient centrifugation within 24 hours 
and harvested 48 hours later.  
Upregulation of PHLPP2 expression by a PHLPP2-3’UTR construct requires intact 
miR-17~92 binding sites 
To assess the ability of the PHLPP2 3’UTR to upregulate PHLPP2 protein by acting as a 
sponge for miR-17~92 transcripts, we cloned the 3’UTR of PHLPP2 from the genomic 
DNA of 01,01 (M4) AML patient cells into an expression vector. PHLPP2 protein levels 
increased in a concentration-dependent manner with increasing amounts of the 3’UTR 
construct in transiently transfected HEK 293 cells (Figure 2-7A). To check expression of 
the 3’UTR while differentiating between the endogenous and transfected 3’UTR 
transcripts, we designed “Internal” and “Overlap” primers (Figure 2-7C). Figure 2-7D 
shows that stably transfected HL-60 (M3/M4) and U937 (M5) cells expressed higher levels 
of the internal 3’UTR fragment than control transfectants (CV). Importantly, expression of 
this exogenous 3’UTR caused upregulation of PHLPP2 proteins, particularly in HL-60 cells 
(Figure 2-7B) without affecting PHLPP2 transcript levels in stably transfected cells (Figure 
2-7E). Finally, to confirm the specificity of the PHLPP2 3’UTR as a miR-17~92 sponge, 
we mutated all miR-17~92 miRNA binding sites in the 3’UTR construct (Figure 2-4). The 
mutated 3’UTR construct no longer induced PHLPP2 expression in either HEK-293 or HL-
60 cells (Figure 2-7F). Interestingly, the 3’UTR transfected HL-60 cells with higher 
PHLPP2 expression showed a slower growth rate than controls (Figure 2-7G).  These 
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results suggest that the miR-17~92 cluster is a major regulator of PHLPP2 protein 
expression in AML.  
 
Figure 2-7. Upregulation of PHLPP2 protein expression by a PHLPP2-3’UTR construct 
requires intact miR-17~92 binding sites. A. Expression of PHLPP2 in HEK-293 cells after 
transfection with the indicated concentrations of pcDNA3.1 plasmid (CV), or PHLPP2 3’UTR 
constructs. The PHLPP2 bands were analyzed by densitometry and normalized to the 
corresponding β-Actin band. B. pcDNA3.1 or 3’UTR constructs were transfected into HL-60 and 
U937 cells. 72 hours after transfection, the cells were cultured in G418-contained medium. The 
stably-transfected cells were collected to check protein levels. C. phlpp2 gene region and the 
location of PCR primers. Green primers (Overlapping) amplify a region overlapping the open 
reading fragment (OFR) and 3’UTR region. Purple primers (Internal) amplify a region internal and 
exclusive to the 3’UTR. D. The mRNA levels of the “Overlapping” and “Internal” fragments were 
detected. E. HL-60 or U937 stably transfected cell were assayed for PHLPP2 mRNA levels. F. 
Expression of PHLPP2 in HEK-293 cells and HL-60 cells after transfection with pcDNA3.1 plasmid 
(CV), wild type 3’UTR construct (WT) or mutant 3’UTR construct (MUT). G. 3’UTR transfected HL-
60 cells showed reduced rate of growth. 1x105 cells were put into fresh medium and the cells were 
counted every 24 hours for 4 days.  
Conclusion 
As a tumor suppressor PHLPP is deleted in many cancers, while others show reduced 
mRNA and protein levels. Studies on PHLPP family proteins have focused on solid tumors 
[O’Neill et al., 2012]. We show, for the first time, that PHLPP2 is suppressed in more 
differentiated AML subtypes, M3 - M5, identified based on the FAB (French American 
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British) classification. The differential expression of PHLPP2 in specific AML subtypes 
suggests it has potential as a biomarker. In both AML cell lines and patient samples, 
PHLPP2 protein levels are negatively correlated with miR-17~92 cluster levels. In addition, 
when miR-17~92 cluster is inhibited PHLPP2 expression is de-repressed. In conclusion, 
this study provides direct physiological evidence that PHLPP2 protein expression is 
suppressed post-transcriptionally by miR-17~92 cluster in AML.  
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Chapter 3 
MiR-17~92 cluster and PHLPP2 expression are regulated 
by C/EBPβ during ATRA induced differentiation in AML  
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Introduction 
In the previous chapter, we showed PHLPP2 protein expression was reduced in specific 
AML subtypes (M3-M5). We also showed that PHLPP2 expression was controlled by miR-
17~92 cluster in these AML cells. The cluster, known as oncomir-1, enhances cell 
proliferation or inhibits apoptosis by suppressing targets such as Bim, E2F1 and PTEN 
and is markedly overexpressed in human cancers [Mogilyansky and Rigoutsos, 2013]. 
The important role of miR-17~92 cluster in tumorigenesis prompted us to investigate its 
regulation in the AML cells. Transcription factor c-MYC and members of the E2F family 
are the major known activators of the miR-17~92 cluster, while p53 acts as a repressor 
under hypoxic conditions [O’Donnell et al., 2005; Sylyestre et al., 2007; Woods et al., 2007; 
Yan et al., 2009]. A TFSEARCH scan of the region 3000 nucleotides upstream of the miR-
17~92 cluster identified two potential binding sites in the transcription factor C/EBPβ. 
Notably C/EBPβ is a downstream target of ATRA, a clinical drug used to treat APL (M3 
AML subtype) patients. In the studies described below we investigate the regulation of 
miR-17~92 cluster and subsequent PHLPP2 expression by the transcription factors 
mentioned above and by the drug ATRA.  
Results 
Expression of miRNA-17~92 cluster in AML is not controlled by transcription factors 
c-MYC or E2F 
The miR-17~92 cluster was reported to be directly activated by the c-MYC oncogene or 
E2F transcription factors in a cell type specific manner [Olive et al., 2013; O’Donnell et al., 
2005; Sylvestre et al., 2007; Woods et al., 2007]. We checked whether either of these 
transcription factors were controlling PHLPP2 expression through miR-17~92 in AML cells.  
First, silencing c-myc in HL-60 cells (Figure 3-1A) showed no significant effect on the miR-
17~92 primary transcript (Figure 3-1B), individual mature miRNAs belonging to miR-17~92 
cluster (Figure 3-1C) or on PHLPP2 protein levels (Figure 3-1D). The reduction in Bim 
protein expression following loss of c-myc, is likely due to the direct regulation of Bim by 
c-myc rather than miR-17~92 [Campone et al., 2011]. Similarly, c-myc silencing affected 
neither miR-17~92 transcript nor PHLPP2 protein levels in U937 AML and K562 CML cells 
(data not shown).  We also used siRNA to silence E2F1 and E2F3 expression, individually 
or together, in HL-60 cells (Figure 3-1E). Again, miR-17~92 primary transcript (Figure 3-
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1F) and mature miRNA levels (not shown) were unaffected, indicating that E2F did not 
control this miRNA cluster in AML. PHLPP2 protein expression also remained unchanged 
(Figure 3-1E). We conclude that regulation of both the miR-17~92 cluster and subsequent 
PHLPP2 expression were independent of c-myc and E2F transcriptional factors in AML 
and, possibly, in other types of myeloid leukemia.  
 
Figure 3-1. Expression of miRNA-17~92 cluster in AML is not controlled by transcription 
factors c-MYC or E2F. A. WBs showing c-myc levels in HL-60 cells 72 hours after transfection 
with c-mycsiRNAor control siRNA (NC). B. RT-PCR quantification of miRNA-17~92 primary 
transcript levels in HL-60 cells. C. RT-PCR quantification of individual mature miRNAs from the 
miRNA-17~92 cluster in the transfected HL-60 cells shown in A. miRNA levels were first normalized 
to the internal control U6 and then individual miRNA levels in si-c-myc cells were further normalized 
against the negative controls. D. PHLPP2 and Bim protein levels in WBs of HL-60 cells 72 hours 
after transfection with c-myc or control siRNAs. PHLPP2 protein expression in K562 cells was used 
as a positive control for the PHLPP2 band on the blot. E. WBs showing E2F protein levels in HL-
60 cells silenced for E2F1 or E2F3 expression, or both, along with negative control, NC. F. Fold 
change in miRNA-17~92 primary transcript levels in HL-60 cells silenced for E2F1 or E2F3 
expression individually or together, 72 hours after transfection of the siRNA.  
ATRA induces PHLPP2 expression by suppressing the miR-17~92 cluster during 
granulocytic differentiation 
All-trans-retinoic-acid (ATRA) reduces the proliferation rate of HL-60 cells and activates 
their terminal differentiation into granulocytes [Breitman et al., 1980; Cull et al., 2014; 
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Degos et al.,1995; Gallagher et al., 1979]. Based on our observation that PHLPP2 3’UTR-
transfected HL-60 cells had a reduced growth rate compared to control vector-transfected 
cells (Figure 2-7G), we asked whether PHLPP2 levels changed during ATRA-induced 
differentiation and whether this effect was mediated through the miR-17~92 cluster. Figure 
3-2A shows that PHLPP2 protein was dramatically induced upon treatment of HL-60 cells 
with ATRA for 3 to 5 days. Cell surface differentiation marker CD11b correspondingly 
increased in a concentration- and time-dependent manner (Figure 3-2B). We also 
detected a reduction in Thr389 phosphorylation of pS6K, a major PHLPP2 substrate, in 
cells exposed to ATRA for 3 days (Figure 3-2C). However, phosphorylation of Akt Ser 473, 
a second PHLPP2 target, increased (data not shown). These results were consistent with 
published studies showing Akt was phosphorylated and activated following ATRA 
treatment [Billottet et al., 2009] and suggested that pS6K was the primary target of 
PHLPP2 during ATRA-induced differentiation.  Additionally, ATRA had no effect on 
PHLPP2 mRNA levels (Figure 3-2D) while miR-17~92 cluster family members decreased 
by almost 50% in HL-60 cells in 3 days (Figure 3-2E). Consistent with the reduction in 
individual miRNA levels, the primary cluster transcript also decreased with ATRA 
treatment (data not shown), confirming that ATRA-mediated differentiation inhibits 
transactivation, rather than processing, of the cluster. Coordinate changes in PHLPP2 and 
miR-17~92 expression levels during ATRA-induced differentiation offered further evidence 
of posttranscriptional inhibition of PHLPP2 by the miR-17~92 cluster and supported the 
hypothesis that this regulation occurred through an ATRA-mediated signaling pathway.  
The reduced inhibition of PHLPP2 expression by the miR-17~92 cluster during ATRA 
treatment, suggests this could be a primary mode of action of the drug. Moreover, the 
increased rate of differentiation of HL-60 cells stably over-expressing the PHLPP2-3’UTR 
in response to ATRA (Figure 3-3A and 3-3B), support this possibility. Thus, ATRA exerts 
its function, at least in part, by reversing the oncomir-1-mediated post-transcriptional 
inhibition of PHLPP2.   
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Figure 3-2. ATRA induced granulocytic differentiation in promyelocytic AML is accompanied 
by PHLPP2 induction and suppression of the miR-17~92 cluster. A. WBs showing PHLPP2 
protein levels in HL-60 cells induced to differentiate in the presence of ATRA. B. Differentiation of 
HL-60 cells treated with 0.1μM or 1 μM ATRA for 3 days or 5 days was monitored through flow 
cytometric detection of CD11b. C. Thr389S6K phosphorylation levels were reduced in HL-60 cells 
treated with 0.1μM or 1μM ATRA for 3 days. D. PCR analysis of PHLPP2 mRNA in ATRA-treated 
HL-60 cells. E. miRNA-17~92 cluster levels in response to ATRA treatment. Individual miRNAs 
from ATRA treated cells and controls were quantified through RT-PCR and normalized to the 
internal control U6. Shown in the graph is the fold change in individual miRNA levels in ATRA-
treated cells compared to untreated controls. 
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Figure 3-3. ATRA-induced differentiation is promoted when miR-17~92 cluster is inhibited 
in 3’UTR cells. A. Rate of differentiation of pcDNA3.1 (CV) and 3’UTR transfected HL-60 cells 
treated with 1 μM ATRA for 3 days was monitored by detection of the surface marker CD11b. 
Shown are representative data from one of three independent experiments. The results from the 
three experiments are quantified in B.  
PHLPP2 protein levels are correlated with miR-17~92 cluster levels in APL patient 
samples 
We also compared PHLPP2 protein expression and miR-17~92 cluster levels in cells from 
APL (M3) patients with those of a less mature (M0) AML patient sample. Both APL patient 
samples tested expressed substantially reduced levels of PHLPP2 protein (Figure 3-4A). 
Furthermore, all four APL samples tested had higher expression of individual miRNAs 
from the miR-17~92 cluster than M0 AML cells (Figure 3-4B). The consistently negative 
correlation between PHLPP2 protein levels and miR-17~92 transcripts in APL patient 
samples underscores the physiological relevance of this regulatory pathway. 
 
Figure 3-4. PHLPP2 protein levels are correlated with miR-17~92 cluster levels in APL patient 
samples. A. WBs showing PHLPP2 protein levels in two APL patient samples and an M0 AML 
patient sample. B. Individual miRNA-17~92 cluster transcript levels in four patient samples were 
quantified using RT-PCR and plotted as a fold change compared with levels in the M0 patient cells.  
ATRA induced down-regulation of the miR-17~92 cluster is mediated through 
transcription factor C/EBPβ 
ATRA activates the expression of a number of target genes involved in myeloid cell 
differentiation through interaction with nuclear receptor and transcription factor RARα 
[Takitani et al., 2003; Zhang et al., 2000]. A scan of the region upstream of the miR-17~92 
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cluster revealed putative binding sites for CCAATT enhancer binding protein and 
transcription factor family member, C/EBPβ, a major ATRA target. The activation of 
C/EBPβ is an early event in the ATRA-induced differentiation response [Duprez et al., 
2003; Huber et al., 2012]. We first determined the concentration- and time-dependent 
induction of C/EBPβ in the HL-60 cell line (Figure 3-5A). Transfection of C/EBPβ siRNA 
abrogated the drug’s ability to upregulate C/EBPβ protein levels (Figure 3-5B) and slowed 
the rate of ATRA-induced differentiation in the HL-60 cells (Figure 3-5C). Both miR-17~92 
primary transcript and mature miRNA levels were reduced in control siRNA expressing 
HL-60 cells exposed to ATRA, but not in C/EBPβ-silenced cells (Figure 3-5D and 3-5E), 
suggesting that the ATRA-induced down-regulation of the cluster was dependent on 
C/EBPβ. The decreased miR-17~92 transcripts in the untreated C/EBPβ knockdown cells 
remained unresponsive to ATRA and suggest an additional, ATRA-independent 
mechanism for control of the microRNA cluster by C/EBPβ. PHLPP2 protein was also 
suppressed in the C/EBPβ-silenced HL-60 cells following ATRA treatment (Figure 3-5F).  
 
Figure 3-5. ATRA induced down-regulation of the miR-17~92 cluster is mediated through 
transcription factor C/EBPβ. A. WBs showing C/EBPβ protein levels in HL-60 cells treated with 
two concentrations of ATRA for 3 and 5 days. B. HL-60 cells were transfected with C/EBPβ and 
control siRNA. 24 hours later cells were treated with 1μM ATRA for 3 days. Induction of C/EBPβ 
and efficiency of silencing was confirmed by WB. C.  C/EBPβ silenced cells and controls were 
treated with 1μM ATRA for 4 days and appearance of the differentiation marker CD11b was 
detected by flow cytometry. Shown are representative data from three independent experiments. 
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D. siRNA transfected cells were treated with 1μM ATRA for 3 days and miR-17~92 primary 
transcript levels were quantified by RT-PCR. E. RT-PCR quantification of individual miRNAs in 
siRNA transfected HL-60 cells with or without ATRA treatment. F. WBs showing PHLPP2 levels in 
control (NC) and C/EBPβ silenced HL-60 cells following exposure to ATRA for 3 days. 
C/EBPβ binds to the intronic promoter of the miR-17~92 cluster 
The miR-17~92 cluster is an intronic cluster, reported to harbor intronic miRNA promoters 
[Monteys et al., 2010]. A TFSEARCH scan of the region 3000 nucleotides upstream of the 
miR-17~92 cluster identified two response elements matching the C/EBPβ DNA binding 
consensus sequence RTTGCGYAAY [Osada et al., 1996], roughly 600 bp (-609 to -600) 
and 1050 bp(-1051 to -1042) upstream of mir-17~92, respectively (Figure 3-6A). To 
determine whether C/EBPβ bound directly to any of these putative response elements, we 
performed a chromatin immunoprecipitation (ChIP) assay. We designed two PCR 
amplicons for the putative binding sites and a third for a region without C/EBPβ binding 
sites.  C/EBPβ was enriched at the distal but not at the proximal promoter region, following 
ATRA treatment (Figure 3-6B). Furthermore, RNA polymerase II was enriched at this 
region in untreated cells, but not detected following ATRA treatment. The replacement of 
RNA pol II at this site by ATRA-induced C/EBPβ supports our hypothesis that the 
transcription factor inhibits miR-17~92 transcription. We also detected some, albeit 
weaker, C/EBPβ interaction with the second predicted (-600bp) element upon ATRA 
treatment. Although we cannot rule out the presence of C/EBPβ at the proximal promoter 
we may be detecting distal binding with proximal probes, given the short distance (~450 
bp) between the two regions.  Regardless, our data strongly support a repressive function 
for C/EBPβ at the distal promoter. Figure 3-6C shows quantitatively that the interaction 
between RNA pol II with Amplicon 1 was significantly reduced and interaction of C/EBPβ 
with this site increased following ATRA treatment. These data demonstrate that C/EBPβ 
interacts directly with the mirR-17~92 intronic promoter and, more importantly, that this 
interaction represses the transcription of this oncomir. Together with our previous 
observations (Figure 3-1), the ChIP assay provides strong evidence supporting our 
hypothesis that transcription factor C/EBPβ, rather than c-MYC or E2F, regulates miR-
17~92 cluster expression in AML. 
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Figure 3-6. C/EBPβ binds to the intronic promoter of the miR-17~92 cluster. A. Schematic 
representation of the upstream region of miR-17~92 cluster (not to scale). Putative C/EBPβ binding 
sites are shown as asterisks and consensus sequences are italicized in parentheses. PCR 
amplicons 1, 2, and 3 are shown as numbered lines. B. HL-60 cells were treated with 1μM ATRA 
for 3 days and subjected to a ChIP assay to detect the interaction between RNA polymerase II (Pol 
II) or C/EBPβ with the amplicons1, 2 and 3 shown in A. C. RT-PCR was performed to measure the 
levels of the binding of Pol II or C/EBPβ with amplicon 1 (containing the 1050 binding site) in HL-
60 cells treated with 1μM ATRA for 3 days. 
Conclusion 
In this chapter, we demonstrate that miR-17~92 cluster levels decrease leading to 
subsequent PHLPP2 upregulation during ATRA induced granulocytic differentiation in 
AML cells.  Mechanistically, our study showed that the regulation of miR-17~92 and 
PHLPP2 by ATRA was mediated through a transcription factor C/EBPβ which competed 
with RNA polymerase II to interact with the intronic promoter of the mir-17~92 cluster, thus 
inhibited the transactivation of this microRNA cluster and led to the upregulation of 
PHLPP2. The model in Figure 3-7 illustrates ATRA mediated regulation of miR-17~92 and 
PHLPP2 expression in AML.   
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Figure 3-7. A model for ATRA-mediated regulation of tumor suppressor phosphatase, 
PHLPP2, in AML cells. In unperturbed AML cells RNA Polymerase II binds to and activates the 
miR-17~92 cluster.  These miRNAs (colored hairpins) bind to the 3’UTR of PHLPP2 and inhibit its 
translation. ATRA treatment leads to the upregulation of C/EBPβ, which binds the miR-17~92 
intronic upstream region distally, preventing RNA Polymerase II from binding and inhibiting 
transcription of the cluster. This releases the block on PHLPP2 translation allowing the 
phosphatase to accumulate in the cells and repress growth and proliferation through inactivation of 
key oncogenic substrates, such as S6K. 
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Chapter 4 
PHLPP2 regulates cellular response to metabolic stress 
through a novel target - AMPK 
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Introduction 
In this chapter, we continue with our investigation of PHLPP2 regulation in hematological 
malignancies, such as leukemia. Our previous study focused on its post-transcriptional 
repression by the miR-17~92 cluster in AML cells, where PHLPP2 protein expression is 
significantly reduced, and also identified a novel pathway for up-regulation of the 
phosphatase through repression of the oncomir-1 cluster by C/EBP, an ATRA-induced 
transcription factor. Here we focus on the role and regulation of PHLPP2 in leukemias, 
such as acute lymphocytic leukemia, which tolerate relatively high levels of the protein. 
The discovery, through an independent study in the Kelekar lab, that PHLPP2 was a 
component of a glucose sensitive multi-protein particle in the cytosol of Jurkat T-ALL cells, 
prompted us to ask whether PHLPP2 played a role in glucose metabolism. Our 
investigations have led to the identification of the energy sensing kinase AMPK as a new 
(fifth) target of PHLPP2, and to the discovery of a novel metabolic role for the protein in 
the cellular response to metabolic stress.  We describe these results in the following 
sections. 
Results 
Inhibition of PHLPP2 protects against cell death from metabolic stress by activating 
AMPK 
The presence of PHLPP2 in a glucose sensitive multi-protein complex (data not shown) 
in Jurkat T-ALL cells, suggested to us that PHLPP2 may have a role to play in glucose 
metabolism. Targeted metabolomic analyses using a [13C]-labeled isotopomer of glucose 
as a tracer showed no difference in glycolytic intermediates between control cells and 
PHLPP2 knockdown cells (data not shown). Unexpectedly, however, we observed a 
dramatic increase in the AMP/ATP ratio and ADP/ATP ratio when PHLPP2 was silenced 
(Figure 4-1A). We then checked the oxygen consumption rate (OCR), which is associated 
with ATP production, in Jurkat cells either silenced for PHLPP2 or over-expressing the 
protein, using a Seahorse Extracellular Flux Analyzer.  Basal OCR levels dropped in the 
absence of PHLPP2 and increased following over-expression of PHLPP2 basal OCR 
(Figure 4-1B-D), compared to controls, supporting the possibility that PHLPP2 was 
affecting the AMP/ATP ratio by regulating ATP production.  
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AMP-activated kinase (AMPK) is the key energy sensor regulating intracellular energy 
homeostasis [Carling et al., 2011]. Cells undergoing metabolic stress increase their 
AMP/ATP ratio and activate the AMPK protein though phosphorylation of subunit AMPKα 
at Thr172 [Hawley et al, 1996]. AMPK was previously shown to be de-phosphorylated by 
PP2C phosphatases, although a specific AMPK phosphatase is yet to be discovered 
[Stephen et al., 1995; Stein et al., 2000]. Since PHLPP proteins are PP2C-type 
phosphatases [Warfel and Newton, 2012], we tested the possibility that AMPK was a 
PHLPP2 substrate.  
To expose Jurkat cells to intracellular energy stress, we cultured the cells in medium with 
5mM glucose, in addition to the ‘complete’ 10mM glucose medium. Lower PHLPP2 protein 
levels allowed the cells to survive better under metabolic stress (Figure 4-2A), but the 
phosphorylation levels of known downstream targets of PHLPP2, phospho-Akt and 
phospho-S6K, were unaffected under these conditions (Figure 4-2B). However, as shown 
in Figure 4-2C, T172 phosphorylation of AMPKα significantly increased when PHLPP2 was 
silenced. The phosphorylation of Acetyl-CoA Carboxylase (ACC) and ULK1, direct 
downstream targets of AMPK [Mack et al., 2012; Inoki et al., 2003], was also enhanced 
in the absence of PHLPP2, particularly under low glucose conditions. Thus, the 
consequence of PHLPP2 silencing in the T-ALL cells was increased phosphorylation, not 
of known oncogenic kinases Akt and S6K, rather of a novel kinase, AMPK, leading to 
activation of its downstream signaling pathways.  
To determine whether the increased viability of PHLPP2-silenced cells under metabolic 
stress was due to regulation of AMPK activity and signaling, we repeated the experiments 
in presence of the AMPK inhibitor, Compound C [Zhou et al., 2001; Handa et al., 2011]. 
As shown in Figure 4-2D, Compound C abrogated the protective effect of PHLPP2 
knockdown in low glucose conditions, suggesting that PHLPP2 was, indeed, regulating 
cell viability through AMPK.  We also exposed Jurkat cells to a small molecule PHLPP2 
inhibitor [Sierecki et al., 2010] and, again, detected no change in phospho-AKT levels, 
but observed, instead, upregulation of phospho-AMPKα and its downstream target, 
phospho-ACC (Figure 4-2E). Thus, both genetic silencing as well as pharmacologic 
inhibition of PHLPP2, could increase AMPK phosphorylation.  
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PHLPP2 is a member of the PHLPP family of phosphatases and PHLPP1 and 2 are known 
to have common targets [O’Neill et al., 2013]. To check whether PHLPP1 affected 
viability and AMPK phosphorylation in a manner similar to PHLPP2 we silenced PHLPP1 
and PHLPP2, either singly or together, in Jurkat cells (Figure 4-3A). Figure 4-3B shows 
that only PHLPP2 silencing had the effect of increasing cell viability under metabolic stress. 
Additionally, PHLPP1 knockdown had no effect on the phosphorylation of AMPKα (Figure 
4-3C). We conclude from these data that regulation of AMPKα phosphorylation and cell 
viability under metabolic stress is unique to PHLPP2. 
 
Figure 4-1. PHLPP2 regulates AMP/ATP ratio and oxidative phosphorylation. A. AMP/ATP or 
ADP/ATP ratios increase in the absence of PHLPP2. The total ATP, ADP and AMP were 
determined by mass spectrometry in Jurkat T cells transfected with control siRNA or PHLPP2 
siRNA. AMP/ATP or ADP/ATP ratios in PHLPP2 knock down cells were calculated and normalized 
to those in control cells. B. Jurkat cells were transfected with control siRNA (NC) or PHLPP2 siRNA 
and oxygen consumption rate (OCR) was measured 72 hours after transfection using a Seahorse 
extracellular flux analyzer. C. OCR was measured in pcDNA control cells and PHLPP2 over-
expressing cells. D. Bar graph showing basal OCR from the Seahorse profiles in C and D. The 
basal OCR in PHLPP2 knock down cells was normalized to that in control siRNA cells (NC) and 
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the basal OCR in PHLPP2 over-expressing cells was normalized to that in pcDNA transfected 
control cells.  
 
Figure 4-2. PHLPP2 downregulation protects against cell death from metabolic stress by 
activating AMPK.  A. Jurkat cells were transfected with control siRNA (NC) or PHLPP2 siRNA (Si-
PHLPP2) and, 24 hours after transfection, cultured in high glucose medium (Glu 10mM) or low 
glucose medium (Glu 5mM) for 4 days. Cell viability was measured by flow cytometric analysis of 
Annexin V/PI uptake. B. Western blots of phospho-AKT (S473), phospho-S6K (T389) and total AKT 
and S6K protein levels in control siRNA cells (NC) or PHLPP2 siRNA cells (Si-P) transfected Jurkat 
cells, 3 days after growth in medium with 10 mM glucose or 5 mM glucose phospho-protein. C. 
Western blots showing phosphorylation of AMPKα (T172), and its downstream targets, ACC and 
ULK1, in the experiment described in 4-2B above. D. The pro-survival effect of si-PHLPP2 under 
metabolic stress is diminished in the presence of AMPK inhibitor, Compound C. Jurkat cells were 
cultured for 4 days in 10 mM glucose medium or 5 mM glucose medium with or without 2 μM 
Compound C 24 hours after transfection with control siRNA (NC) or PHLPP2 siRNA (Si-PH2). Cell 
viability was measured by flow cytometric analysis of Annexin V/PI staining. E. Phosphorylation of 
AMPKα increases in the presence of a PHLPP2 inhibitor. Jurkat cells were treated with a PHLPP2 
inhibitor for 72 hours and phospho-protein and total protein levels were detected by western blot.  
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Figure 4-3. PHLPP1 does not affect AMPK-phosphorylation or the cellular response to 
metabolic stress in Jurkat cells. A. PHLPP1 and PHLPP2 were silenced in Jurkat cells, either 
singly or together using siRNA. Jurkat cells were transfected with control siRNA (NC), PHLPP1 
siRNA, PHLPP2 siRNA or both. 72 hours after transfection. Cells were collected to check the 
knockdown efficiency. B. Cell viability of Jurkat cells under low glucose conditions following PHLPP 
silencing. Jurkat cells were transfected with control siRNA (NC), PHLPP2 siRNA (Si-PH1), PHLPP2 
siRNA (Si-PH2) or both (Si-PH1+2) and 24 hours after transfection the cells were cultured in high 
glucose medium (Glu 10mM) or low glucose medium (Glu 5mM) for 4 days. Cell viability was 
measured by flow cytometric analysis of Annexin V/PI staining. C. PHLPP1 silencing does not affect 
AMPKα (T172) phosphorylation level. Western blot shows pAMPKα (T172) levels PHLPP1 protein 
was silenced. 
Absence of PHLPP2 promotes AMPK phosphorylation and prevents the inhibition 
of AMPK 
AMPK, an energy sensing kinase, is phosphorylated and activated under nutrient stress 
through binding of AMP to the AMPKγ subunit [Hawley et al, 1996]. AICAR (5-
Aminoimidazole-4-carboxamide ribonucleotide), as an AMP mimetic, also binds to the 
AMPKγ subunit to induce the phosphorylation of AMPKα and activation of AMPK [Corton 
et al, 1995]. Both glucose deprivation and AICAR treatment increased phosphorylation 
of AMPKα (T172) when PHLPP2 was silenced (Figure 4-4A). AICAR also promoted survival 
of Jurkat cells in low glucose induced stress conditions (Figure 4-4B), indicating that 
activation of AMPK had a growth promoting effect in Jurkat leukemia cells, consistent with 
the effects observed with inhibition of PHLPP2 (Figure 4-2A). Next, we looked at the effect 
of PHLPP2 on AMPK phosphorylation over 24 hours of glucose deprivation. 
Phosphorylation of AMPK decreased within 2 hours of glucose withdrawal in both control 
as well as PHLPP2 silenced cells. However, AMPK phosphorylation was restored at an 
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accelerated pace, within 8 hours, in the absence of PHLPP2, as compared with >12 hours 
in control cells (Figure 4-4C).  
Compound C, as mentioned above, is an AMPK inhibitor that decreases phosphorylation 
of AMPK [Zhou et al., 2001; Handa et al., 2011]. We showed earlier that, at a 
concentration of 2μM, Compound C could override the protective effects imparted by loss 
of PHLPP2 under metabolic stress (Figure 4-2D). We found that lower concentrations (0.5 
μM and 1 μM) of Compound C were unable to inhibit AMPK phosphorylation in PHLPP2 
silenced cells (Figure 4-4D). At higher concentrations (2μM) Compound C strongly 
inhibited phosphorylation of AMPK regardless of PHLPP2 protein levels, consistent with 
the result in Figure 4-2D. However, under low glucose PHLPP2 knockdown was able to 
protect against the death promoting effects of low concentration of the AMPK inhibitor 
(Figure 4-2E). Taken together, our data provide evidence that loss of PHLPP2 expression 
promotes AMPK phosphorylation, prevents AMPK inhibition, and rescues cells from death 
induced by AMPK inhibition. Thus, the PHLPP2 phosphatase regulates the 
phosphorylation and activation of AMPK.  
 
Figure 4-4. Absence of PHLPP2 increases AMPK phosphorylation and prevents the 
inhibition of AMPK. A. Both glucose deprivation and AICAR treatment promote phosphorylation 
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of AMPKα in the absence of PHLPP2. 48 hours after transfection with control siRNA (NC) or 
PHLPP2 siRNA (Si-P), Jurkat cells were cultured in medium without glucose or treated with 0.5 
mM AICAR for 6 hours. Protein level changes were analyzed by WB. B. AICAR treatment prevents 
cell death under metabolic stress. Jurkat cells were culture in Glucose 10 mM medium or Glucose 
5 mM and at the same time the cells were treated with or without 0.2 mM AICAR for 3 days. Cell 
viability was measured by flow cytometric analysis of Annexin V/PI staining. C. PHLPP2 silencing 
accelerates AMPKα phosphorylation and activation observed during glucose deprivation. Jurkat 
cells were transfected with control siRNA (NC) or PHLPP2 siRNA (Si-PHLPP2). Cells were cultured 
in medium without glucose 48 hours after transfection, and p-AMPKα and total AMPK levels 
checked at the indicated time points following glucose deprivation. D. Absence of PHLPP2 
abrogates the inhibitory effect of Compound C on AMPKα. Jurkat cells were transfected with control 
siRNA (NC) or PHLPP2 siRNA (Si-PHLPP2) and, 24 hours later, were exposed to 0.5, 1, 2 μM of 
Compound C for a period of 3 days. Protein levels were detected by WB. E. The ability of 
Compound C to promote death under low glucose conditions is abrogated in the absence of 
PHLPP2.  24 hours after transfection with control siRNA (NC) or PHLPP2 siRNA (Si-PH2) Jurkat 
cells were cultured for 3 days in 10 mM or 5 mM glucose medium with or without 0.5 μM Compound 
C. Cell viability was measured by flow cytometric analysis of Annexin V/PI staining.  
Over-expression of PHLPP2 promotes de-phosphorylation of AMPKα and cell death 
under metabolic stress and requires the PH domain for these functions. 
The PHLPP2 protein has a Ras-Association domain (RA) at the N terminus, a Pleckstrin 
Homology domain (PH), a Leucine Rich Repeat domain (LRR), a PP2C phosphatase 
domain and a PDZ-binding motif at the C terminus (Figure 4-5A) [Gao et al., 2005; 
Brognard and Newton, 2008]. Previous studies have shown that the ability of PHLPP2 
to de-phosphorylate its targets is regulated by the PH domain and PDZ-binding motif [Gao 
et al., 2005; Gao et al., 2008]. Endogenous phospho-AMPKα T172 was significantly 
reduced in Jurkat cells over-expressing full length PHLPP2, but not in cells expressing 
ΔPH or ΔPH/LRR deletion mutants (Figure 4-5B). Exogenous full length PHLPP2 induced 
significant cell death in Jurkat cells under low glucose conditions, and required an intact 
PH domain for this effect (Figure 4-5C).  Since phosphatases are known to interact directly 
with their targets, we checked whether PHLPP2 could interact with AMPK. As shown in 
Figure 4-6A, phospho-AMPKα co-immunoprecipitates with endogenous PHLPP2; this 
binding interaction is impaired in the absence of the PH domain (Figure 4-6B). Thus, these 
data offer strong support for PHLPP2 as an AMPK phosphatase, and show that the 
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phosphatase function of PHLPP2, and its ability to promote cell death under metabolic 
stress and to interact with AMPKα are all dependent on the presence of an intact PH 
domain. 
 
Figure 4-5. Over-expression of PHLPP2 promotes de-phosphorylation of AMPKα and cell 
death under metabolic stress and requires the PH domain for these functions. A. The protein 
structure of PHLPP2 and different PHLPP2 inserts in the PHLPP2 constructs. RA: Ras-Associated 
domain. PH: Pleckstrin Homology domain. LRR: Leucine Rich Repeat domain. PP2C: Protein 
Phosphatase 2C domain. B. Over-expression of full-length PHLPP2, not the PH domain deleted 
PHLPP2, induces de-phosphorylation of AMPKα in Jurkat cells. The pcDNA empty vector, PHLPP2 
full-length (FL), PH domain deleted (ΔPH) and PH/LRR domain deleted (ΔPH/LRR) constructs 
were transfected into Jurkat cells. 72 hours after transfection, protein levels were detected by WB. 
C. The PH domain is required for the death promoting effect of over-expressed PHLPP2 under 
metabolic stress. Jurkat cells were transfected with the indicated constructs and 24 hours after 
transfection the cells were cultured in 10mM or 5mM Glucose medium for 4 days. Cell viability was 
measured by flow cytometric analysis of Annexin V/PI staining.  
 
Figure 4-6. PHLPP2 interacts with AMPK and requires the PH domain for the interaction. A. 
Endogenous PHLPP2 interacted with phospho-AMPKα directly. The interaction between PHLPP2 
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and p-AMPKα was detected by protein immunoprecipitation. B. Full-length PHLPP2, but not the 
PH domain deleted mutant, interacts with AMPKα. Jurkat cells were transfected with the indicated 
constructs. 72 hours after transfection, the cells were collected and Flag antibody was used for 
protein immunoprecipitation with the blot probed with AMPKα and PHLPP2 antibodies. 
PHLPP2 dephosphorylates phospho-AMPKα in vitro, and requires the PH domain 
for this function. 
Having shown that PHLPP2 regulates AMPKα phosphorylation intracellularly and can 
interact with AMPKα protein, we developed an in vitro phosphatase assay to assess the 
phosphatase activity of PHLPP2 using recombinant active AMPKα as substrate. In this 
assay, we used either FLAG antibody or PHLPP2 antibody to immuno-precipitate over-
expressed PHLPP2 protein from cell lysates and incubated it with a recombinant purified 
phospho-AMPK protein. After the assay, the phosphorylation level of AMPKα, as an 
indicator of the phosphatase activity of PHLPP2, was determined by western blot. As 
shown in Figure 4-7A, phospho-AMPKα T172 level was significantly reduced in the 
presence of full length PHLPP2 protein and this phosphatase activity was dose-dependent 
(Figure 4-7B). Again, PH domain deleted PHLPP2 was unable to de-phosphorylate p-
AMPKα in the in vitro assay (Figure 4-7C); this could be attributed to the impaired 
interaction between ΔPH PHLPP2 and AMPK shown in Figure 4-6B.  
Thus, we offer additional evidence that PHLPP2 is a phosphatase of AMPK in an in vitro 
assay using a full-length recombinant AMPK protein. Previous studies have used 
phospho-peptides as substrates to assess phosphatase activity of the PHLPP proteins in 
vitro [Gao et al., 2005; Brognard et al., 2007]. This would be the first use of a full-length 
substrate to demonstrate PHLPP2 phosphatase activity. 
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Figure 4-7. PHLPP2 dephosphorylates phospho-AMPKα in vitro, and requires the PH domain 
for this function. A. PHLPP2 de-phosphorylated p-AMPKα in vitro. Jurkat cells were transfected 
with pcDNA empty vector or PHLPP2 full-length construct. 72 hours after transfection, the cells 
were collected and over-expressed PHLPP2 proteins were pulled down using FLAG 
immunoprecipitation and their ability to de-phosphorylate purified recombinant AMPK proteins was 
tested in an in vitro phosphatase assay. Phosphorylation level of AMPKα and total amount of AMPK 
proteins (checked by AMPKβ) were measured by WB. B. PHLPP2 t de-phosphorylates AMPKα in 
a dose-dependent manner. Different amounts of FLAG-PHLPP2 proteins were included in the in 
vitro phosphatase assay. Phosphorylation level of AMPKα and total amount of AMPK proteins 
(checked by AMPKβ) were measured by WBs. C. The ability of PHLPP2 to de-phosphorylate 
AMPKα was impaired when PH domain was deleted. 72 hours after the Jurkat cells were 
transfected with the indicated plasmids, PHLPP2 IP was conducted to pull down full-length or PH-
deleted PHLPP2 proteins. The ability of these PHLPP2 proteins to de-phosphorylate AMPK was 
tested through the in vitro phosphatase assay. The graph on the bottom shows the phosphorylation 
levels of AMPKα normalized to total AMPK level (checked by AMPKβ) after the in vitro assay.  
PHLPP2 regulates phospho-AMPK levels in various cancer cell lines. 
We have shown that PHLPP2 is an AMPKα phosphatase that can regulate the activation 
of the AMPK pathway and the cellular response to metabolic stress in Jurkat acute 
lymphocytic leukemia cells. However, we were unable to detect phosphatase activity on 
41 
 
 
known targets such as pAKT and pS6K in this leukemia model. We checked whether 
PHLPP2 could regulate AMPK phosphorylation in other types of tumor cells. As shown in 
Figure 4-8A, phospho-AMPKα T172 levels increased when PHLPP2 was silenced in two 
leukemia cell lines Molt4 (acute lymphocytic leukemia) and K562 (chronic myeloid 
leukemia). Importantly, this was also observed in two solid tumor cell lines H522 (non-
small cell lung cancer) and DLD1 (colorectal adenocarcinoma), suggesting that PHLPP2 
functions as an AMPKα phosphatase in a wide variety of cell types. It must be noted that, 
while the absence of PHLPP2 protected against cell death induced by metabolic stress in 
K562 (Figure 4-8C) and H522 cells (Figure 4-8D), it had the opposite effect in Molt 4 
(Figure 4-8B) and DLD1 cells (Figure 4-8E). The differential effect of PHLPP2 in regulating 
cellular response to metabolic stress i.e. whether AMPK has a tumor-suppressive or an 
oncogenic effect, could depend on cellular context. Moreover, novel, as yet unidentified 
targets of PHLPP2 could also contribute to the overall effects of this phosphatase in 
cancer.  
 
Figure 4-8. PHLPP2 regulates phospho-AMPK levels in various cancer cell lines. A. Phospho-
AMPKα levels increased when PHLPP2 was silenced in a variety of cancer cell lines. Molt 4 (acute 
lymphocytic leukemia), K562 (chronic myeloid leukemia), H522 (non-small cell lung cancer) and 
DLD1 (colorectal adenocarcinoma) cells were transfected with control siRNA (NC) or PHLPP2 
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siRNA (Si-PH2). 72 hours after transfection, protein levels were determined by WB. B. Cell viability 
under metabolic stress decreased in the absence of PHLPP2 in Molt 4 cells. siRNA transfected 
Molt 4 cells were cultured in 10 mM or 1 mM glucose medium for 4 days. Cell viability was measured 
by flow cytometric analysis of Annexin V/PI staining. C. Cell viability under metabolic stress 
increased in the absence of PHLPP2 in K562 cells. siRNA transfected K562 cells were cultured in 
10 mM glucose medium or  medium without glucose for 4 days. Cell viability was measured by flow 
cytometric analysis of Annexin V/PI staining. D. Cell viability under metabolic stress increased in 
the absence of PHLPP2 in H522 cells. siRNA transfected H522 cells were cultured in 10 mM 
medium or  medium without glucose for 4 days. Cell viability was measured by flow cytometric 
analysis of Annexin V/PI staining. Glucose. E. Cell viability under metabolic stress decreased in 
the absence of PHLPP2 in DLD1 cells. siRNA transfected DLD1 cells were cultured in 10 mM or 1 
mM glucose medium for 4 days. Cell viability was measured by flow cytometric analysis of Annexin 
V/PI staining.  
Conclusion 
The studies described here identify a new target and a novel function for the PHLPP2 
phosphatase in cancer cell metabolism and energy homeostasis in PHLPP2-expressing 
hematopoietic cancer cells as well as in cell lines derived from solid tumors. The effects 
of silencing PHLPP2 on survival of cells undergoing metabolic stress, and on the 
phosphorylation and activation of the energy sensing kinase AMPK, offer significant 
insights into a unique role for this phosphatase, that is distinct from PHLPP1, a close family 
member. Together these studies demonstrate the ability of PHLPP2 to control the cellular 
response to nutrient stress and to interact with and dephosphorylate AMPK intracellularly 
and in vitro, and show that the Pleckstrin Homology (PH) domain on the protein is 
indispensable for all these functions. Thus, AMPK a novel target of PHLPP2 may be the 
mediator of PHLPP2’s role in cancer metabolism. This will also be the first identification of 
a specific AMPK phosphatase. 
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Chapter 5 
PHLPP2 regulates fatty acid oxidation through AMPK-
ACC pathway 
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Introduction 
In the previous chapter, we described studies that led to the discovery of a new target and 
a new metabolic function for PHLPP2. We showed that PHLPP2 is a phosphatase for 
AMPK, the key energy sensing kinase, and that it regulates the cell’s response to nutrient 
and energy stress. Under metabolic stress, activated AMPK phosphorylates its 
downstream targets to switch on catabolic pathways and switch off anabolic metabolism 
and restore energy homeostasis [Garcia and Shaw, 2017]. We found that under low 
glucose conditions phosphorylation of AMPK targets, ULK1, and particularly ACC1/2, 
increased significantly with PHLPP2 inhibition or loss (Figure 4-2C and 4-2E). 
Phosphorylation of ACC by activated AMPK inhibits its activity which leads to increased 
fatty acid oxidation and decreased fatty acid synthesis [Fullerton et al., 2013]. The 
increase in phospho-ACC levels in response to PHLPP2 protein loss suggested to us that 
the effect of PHLPP2 on cell survival under metabolic stress might be mediated via its 
regulation of fatty acid metabolism through an AMPK-ACC pathway. Studies described in 
this chapter investigate this possibility.  
Results 
PHLPP2 silencing does not affect fatty acid synthesis but increases endogenous 
fatty acid oxidation under nutrient stress. 
To determine whether PHLPP2 influenced fatty acid synthesis we measured the 
incorporation of [14C]-acetate into triacylglycerols (TAG) and phospholipids (PL). 
Knocking down PHLPP2 expression in Jurkat cells did not significantly affect the rate of 
de novo lipogenesis as shown in Figure 5-1A. To check fatty acid oxidation (FAO) rate we 
determined the sensitivity of the oxygen consumption rate (OCR) to FAO inhibition. Long 
chain fatty acids are transported to the mitochondrial matrix through carnitine palmitoyl 
transferase (CPT) system [Wakil and Abu-Elheiga, 2009].  In the mitochondria, fatty 
acid is oxidized to generate acetyl-CoA which enters the TCA cycle to be further oxidized. 
Electrons derived from these oxidation steps are passed to O2 in the mitochondrial 
respiratory chain, providing the energy for ATP synthesis. For the FAO assay using 
Seahorse, cells are treated with Etomoxir (ETO), a CPT1 inhibitor, which blocks long chain 
fatty acids from entering the mitochondria. Thus, a decrease in OCR with ETO treatment 
is a reliable indicator of intracellular fatty acid oxidation. Carrying out the assay with cells 
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cultured in nutrient-limited medium offers a clue to how the cells utilize fatty acid under 
energy stress. As shown in Figure 5-1B, the OCR in PHLPP2 silenced Jurkat cells was 
significantly more sensitive to ETO (or FAO inhibition) compared to the control group. 
These results suggest that PHLPP2 knockdown promotes fatty acid oxidation in cells that 
are under metabolic stress.  
 
Figure 5-1. PHLPP2 silencing does not affect fatty acid synthesis but increases endogenous 
fatty acid oxidation under nutrient stress. A. The incorporation of [14C]-labelled acetate into 
triacylglycerols and phospholipids was measured to check de novo lipogenesis. B. To evaluate 
fatty acid oxidation using the Seahorse Analyzer, cells (NC or si-PHLPP2 cells) were cultured in 
nutrient-limited medium the previous day. The assay was carried out in the presence or absence 
of Etomoxir to measure the FAO-dependent oxygen consumption rate (OCR). C. Bar graph of FAO 
dependent OCR values (basal OCR W/O ETO minus basal OCR W/ ETO) in NC cells or Si-
PHLPP2 cells. 
PHLPP2 regulates fatty acid oxidation through AMPK 
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To determine whether PHLPP2’s effect on fatty acid oxidation was mediated through the 
AMPK pathway, we inhibited AMPK with Compound C. As shown in Figure 5-2A, 5-2C, 
without Compound C treatment the FAO dependent OCR increased significantly in 
PHLPP2 silenced cells. In the presence of Compound C, however, PHLPP2 knockdown 
could no longer promote fatty acid oxidation (Figure 5-2B, 5-2C), strongly supporting a 
role for PHLPP2 in regulating fatty acid oxidation through an AMPK-ACC route in 
metabolically stressed cells.  
 
Figure 5-2. PHLPP2 regulates fatty acid oxidation through AMPK. A. Fatty acid oxidation was 
measured using a Seahorse FAO assay. The contribution of FAO to the OCR level is determined 
by the reduction in OCR following Etomoxir treatment. B. The increased FAO observed in the 
absence of PHLPP2 was reversed by AMPK inhibitor Compound C. Jurkat cells was transfected 
with control siRNA (NC) or PHLPP2 siRNA (si-PH2) and 24 hours after transfection, treated with 
Compound C. 24 hours later, the cells were cultured in nutrient-limited medium for one day and 
subjected to a Seahorse assay to measure FAO dependent OCR. C. Bar graphs of FAO dependent 
OCR values (basal OCR W/O ETO minus basal OCR W/ETO) in NC cells or Si-PHLPP cells without 
or with Compound C from the experiment profiled in A and B.  
PHLPP2 knockdown promotes cell survival under metabolic stress by increasing 
fatty acid oxidation 
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In the previous chapter, we showed that the absence of PHLPP2 promoted cell survival 
under energy stress by inducing the phosphorylation and activation of AMPK. Here we 
asked whether the increased fatty acid oxidation was contributing to the pro-survival effect 
of PHLPP2 knockdown. We found that the cell survival effect of PHLPP2 knockdown 
under low glucose conditions was dampened in the presence of the fatty acid oxidation 
inhibitor, ETO (Figure 5-3A), which suggested that the effect of PHLPP2 on the cellular 
response to metabolic stress was mediated, at least in part, through its effect on fatty acid 
oxidation. 
 
Figure 5-3. PHLPP2 knockdown promotes cell survival under metabolic stress by increasing 
fatty acid oxidation. A. The pro-survival effect of PHLPP2 knockdown was reversed by FAO 
inhibitor Etomoxir. Jurkat cells were transfected with control siRNA (NC) or PHLPP2 siRNA (Si-
PH2) and, 24 hours post-transfection, cultured for days in medium containing either 10mM or 5mM 
glucose, in the presence of absence (Con) of Etomoxir, before analysis of cell viability was analyzed 
by flow cytometry. B. simplified model depicting our current understanding of the role of PHLPP2 
in modulating energy homeostasis under metabolic stress, through regulation of AMPK and fatty 
acid oxidation (FAO). 
Conclusion 
The experiments described in this chapter provide the first evidence of a role for PHLPP2 
in regulating fatty acid oxidation (FAO) under conditions of nutrient limitation, and 
demonstrate that this role is mediated through AMPK signaling. When glucose supplies 
are low, Jurkat cells can use FAO to support ATP production, and for survival, only in the 
absence of PHLPP2, suggesting that PHLPP2 promotes cell death under nutrient stress 
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at least in part by preventing the switch to FAO. Additional pathways that are regulated by 
AMPK may also contribute to the effect of PHLPP2 on the cellular response to energy 
stress and will be investigated. The model in Figure 5-3B illustrates our current 
understanding of how PHLPP2 modulates energy homeostasis under metabolic stress 
though regulation of AMPK and fatty acid metabolism. 
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Chapter 6 
Discussion 
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Phosphatases are central players in signaling pathways that antagonize both cell survival 
and the cancer phenotype and the PHLPP family of serine threonine phosphatases, in 
particular, with oncogenic kinases as targets [Brognard and Newton, 2008], are emerging 
as important tumor suppressors [O’Neill et al., 2013]. The focus of this dissertation is the 
phosphatase, PHLPP2, in myeloid and lymphoid leukemia cells. This study makes major 
contributions to our understanding of the regulation, expression and function of PHLPP2, 
identifying a novel regulatory mechanism, a prominent energy sensing kinase as a new 
substrate, and a novel metabolic function for the phosphatase. 
Regulation of PHLPP2 in AML 
Studies on PHLPP family proteins have focused on solid tumors, such as prostate, 
colorectal and breast cancers, as well as melanomas and non-small cell lung cancers 
[O’Neill et al., 2013]. As a tumor suppressor PHLPP is deleted in many cancers, while 
others show reduced mRNA and protein levels. Here we demonstrate for the first time, 
that PHLPP2 is suppressed in the more differentiated AML subtypes, M3, M4 and M5, by 
miRNAs belonging to the miR-17~92 cluster, oncomir-1. The FAB system [Lowenberg et 
al., 1999] sorts AML on the basis of morphology, cell type and degree of differentiation in 
contrast to the broader WHO classification, which takes into account factors that impact 
prognosis. The differential expression of PHLPP2 in specific AML subtypes underscores 
its potential as a biomarker and a therapeutic target. Differential expression of the miR-
17~92 cluster across FAB subtypes also suggests developmental regulation. We show 
that the phosphatase is significantly upregulated in AML cells induced towards 
granulocytic differentiation by ATRA, a drug used for treating AML, through repression of 
the miR-17~92 cluster. Finally, we demonstrate a novel role for transcription factor 
C/EBPβ, a mediator of ATRA–induced differentiation, in direct repression of the miR-
17~92 cluster leading to upregulation and activation of PHLPP2. These findings are 
summarized in the model depicted in Figure 3-7. 
The miR-17~92 cluster is frequently amplified in several lymphomas and in lung cancer 
[Hayashita et al., 2005; Ota et al., 2004], and aberrant overexpression of the miR-17~92 
polycistron is detected in many cancers [Garofalo et al., 2011]. Retinoblastoma-like 2 
protein (p130, Rbl2), Cdk inhibitor p21CIP1, transforming growth factor β1 (TGFβ1), pro-
apoptotic Bcl-2 protein Bim, the tumor suppressor PTEN and transcription factor E2F1, 
are some of the cluster’s targets [Olive et al., 2013]. A previous study on drug resistant 
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mantle cell lymphomas with an amplified oncomir-1 cluster had suggested that the chemo-
resistance was mediated largely through PHLPP2 suppression, although this was not 
directly tested in the mantle cell lymphoma model [Rao et al., 2012]. Our studies offer the 
first direct evidence that the miR-17~92 cluster controls PHLPP2 protein levels through 
the 3’UTR of its mRNA.  
The regulated expression of miR-17~92 across AML subtypes, suggests a developmental 
role for these miRNAs. This cluster has already been implicated in the survival signal that 
promotes progression from the pro-B- to pre-B-cell stage during normal B cell 
development, in part through its suppression of Bim protein expression [Ventura et al., 
2008]. Downregulation of the miR-17~92 cluster is essential for induction of normal 
myeloid differentiation orchestrated by myeloid transcription factor PU.1 [Alemdehy et al., 
2012]. Thus, upregulation of the cluster could lead to a differentiation block in specific AML 
subtypes. Our studies suggest that increased expression of the miR-17~92 cluster is not 
controlled by c-MYC or E2F1/3, transcription factors known to upregulate the cluster in 
solid tumors and in some B lymphomas [O'Donnell et al., 2005; Sylvestre et al., 2007; 
Woods et al., 2007], although loss of a repressor in the PU.1 signaling pathway is being 
not ruled out.  We also show that ATRA-induced activation of differentiation in HL-60 cells 
causes significant suppression of the miR-17~92 cluster (Figure 3-2B and 3-2E). 
Suppression and subsequent de-repression of miR-17~92 targets, including PHLPP2 
(Figure 3-2A), are likely to be critical for mediating ATRA’s differentiating effect. The 
increased sensitivity of PHLPP2 3’UTR “sponge”-transfected cells to ATRA (Figure 3-3A 
and 3-3B) support this possibility.  
We show that ATRA target, C/EBPβ, mediates the repression of the oncomir-1 cluster in 
HL-60 cells by interacting directly with a binding site in the intronic promoter of the miR-
17~92 gene (Figure 3-6). Previous studies showed that transcription factors c-MYC and 
E2F bind to the promoter region of the host gene, MIR17HG [O'Donnell et al., 2005; 
Sylvestre et al., 2007; Woods et al., 2007].  In AML cells, neither c-MYC nor E2F silencing 
affected miR-17~92 expression, but C/EBPβ binding to the intronic promoter could repress 
the cluster, suggesting that transcriptional regulation of the miR-17~92 cluster in AML is 
independent of its host gene. C/EBPβ is a member of the C/EBP family of basic 
region/leucine zipper transcription factors, important for differentiation of liver, adipose 
tissue and hematopoietic cells [Duprez et al., 2003]. The C/EBPβ promoter contains 
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binding sites for several transcription factors including retinoic acid receptor a (RARa). 
C/EBPβ can promote either activation or repression of its target genes in a cell- and tissue-
specific manner [Duprez et al., 2003; Huber et al., 2012]. It is one of the major proteins 
induced in response to ATRA, and is essential for granulocytic differentiation. We show 
that the ATRA-induced reduction in miR-17~92 levels requires the presence of C/EBPβ 
(Figure 3-5). The initial drop in miR-17~92 levels in untreated HL-60 cells expressing 
C/EBPβ siRNA compared to controls suggests that the transcription factor may function 
as an activator of miR-17-92 at low concentrations. However, untreated levels were 
unaffected by the addition of ATRA (Figure 3-5D). C/EBPβ has been attributed a tumor-
promoting role in breast and prostate cancer [Bundy et al., 2003; Kim et al., 2008; Zahnow 
et al., 1997] and shown to be a negative regulator of miR-145, a tumor suppressor miRNA 
often downregulated in breast cancer [Sachdeva et al., 2012].  
Interestingly, C/EBPβ that is upregulated in ATRA-treated cells can also bind and activate 
the promoter for master hematopoietic transcription factor PU.1 [Mueller et al., 2006]. 
Suppression of PU.1 is critical to the maturation block at the promyelocytic stage in APL, 
and restoration of its expression by ATRA was suggested to be a major mechanism 
leading to granulocytic differentiation. The significant reduction in miR-17~92 levels and 
in the primary transcript in ATRA treated HL-60 cells (Figure 3-2E and 3-5D) supports the 
possibility that C/EBPβ suppresses miR-17~92 via two pathways – indirectly through 
induction of PU.1 expression, where it functions as an activator, and more efficiently, 
through direct interaction with the miR-17~92 promoter, as we have demonstrated, where 
it functions as a repressor. Overall, these studies establish the significance of PHLPP2 
regulation during AML development and terminal differentiation and provide a foundation 
for future studies aimed at therapeutic targeting of the phosphatase, either directly or via 
C/EBPβ and/or miR-17~92.  
Despite growing interest in their potential therapeutic value as tumor suppressors, 
investigations of PHLPP phosphatases have focused largely on solid tumors. We were 
interested in identifying mechanisms regulating the widely different expression patterns of 
PHLPP2 in leukemia. We believe post-transcriptional inhibition by the oncomir -1 cluster, 
described in chapters 2 and 3, is just one of multiple cell type-specific, regulatory 
mechanisms in leukemia. The second half of my dissertation focuses on a different 
leukemic cell type in which the PHLPP2 protein is constitutively expressed, likely to be 
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regulated via post-translational modifications, and responsive to alterations in the 
metabolic state of the cell. 
PHLPP2 plays a novel metabolic role as a phosphatase for AMPK 
In identifying an important energy sensing kinase, AMPK, as the newest target of PHLPP2, 
our studies also reveal a novel metabolic role for this phosphatase in regulating the cellular 
response to energy stress through AMPK signaling. We showed that PHLPP2 could 
dephosphorylate AMPKα (T172) both in cells and in vitro, and phosphorylation and 
activation of intracellular AMPK protein increased with loss in PHLPP protein levels. 
PHLPP2 loss promoted survival of glucose deprived Jurkat T-ALL cells, suggesting a role 
for the protein in metabolic reprogramming. Most importantly, PHLPP2 regulation of AMPK 
was observed not only in leukemia cells but also in solid tumor-derived cancer lines. Our 
findings from these studies are summarized in a model in Figure 5-3B.  
We provide evidence that AMPK, the new target of PHLPP2, mediates its novel metabolic 
function. When cells are under energy stress and low in ATP, they increase their AMP/ATP 
ratio, causing AMPK to be phosphorylated at T172 by upstream kinases [Carling et al., 
2011]. AMP competes with ATP to bind AMPKγ subunit, causing a conformational change 
and exposing the T172 on AMPKα to phosphorylation by kinases [Hawley et al, 1996]. The 
interaction between AMP and AMPK protein also renders the protein a better substrate 
for kinases, but less than ideal for phosphatases [Gowans et al., 2013]. PHLPP2 regulates 
the intracellular AMP/ATP ratio through its effect on oxidative phosphorylation and ATP 
production (Figure 4-1). Our studies showed PHLPP2 regulates phosphorylation and 
activation of AMPK by dephosphorylating T172 on the alpha subunit, while PHLPP2 
silencing promotes the phosphorylation of AMPK by upstream kinases. Thus, as an AMPK 
phosphatase, PHLPP2 may act as master regulator of AMPK phosphorylation and 
activation through modulation of the intracellular AMP/ATP ratio. 
PHLPP phosphatases inhibit cancer cell proliferation by dephosphorylating Akt, PKC and 
S6k, and induce cell apoptosis by activating Mst1 [O’Neill et al., 2013]. Here, using a Jurkat 
T leukemia cell model, we show that the loss of PHLPP2 promotes cell survival under 
metabolic stress, by increasing AMPK phosphorylation/activation. AMPK activator AICAR, 
had a similar effect under these conditions while AMPK inhibitor Compound C promoted 
death (Figure 4-4B, 4-4E). The above results point to an oncogenic role for AMPK in Jurkat 
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cells.  One study [Jeon et al., 2012] has suggested that AMPK promoted lung tumor cell 
survival during energy stress, supporting our conclusions. Another showed AMPK 
protecting leukemia-initiating cells from metabolic stress in AML [Saito et al., 2015].  Yet 
another, however, showed that AMPKα is a negative regulator of the Warburg effect, and 
that its loss accelerates Myc-driven lymphomagenesis [Faubert et al., 2013]. The opposing 
roles for AMPK in cancer may depend on several factors, including cell type, context and 
the AMPK isoform that is expressed. Emerging evidence suggests that AMPKα2 acts as 
a tumor suppressor, but AMPKα1, the most commonly expressed isoform, is an 
oncoprotein [Hardie, 2017]. However, this needs to be further investigated with respect to 
PHLPP2 regulation of AMPK in Jurkat cells.  
AMPK exerts its oncogenic or tumor suppressive function by regulating glucose 
metabolism, redox homeostasis and fatty acid synthesis/oxidation [Garcia et al., 2017]. In 
Jurkat cells, the increased phospho-AMPKα in PHLPP2 silenced cells significantly 
increased phosphorylation of Acetyl-CoA Carboxylase (ACC) (Figure 4-2C). Previous 
studies have shown that phosphorylation of ACC1 by AMPK inhibited its activity and led 
to a decrease in fatty acid synthesis, and phosphorylation of ACC2 by AMPK led to 
increased β-oxidation [Fullerton et al., 2013]. The studies described in Chapter 5 point to 
a role for PHLPP2 in regulating fatty acid β-oxidation, rather than fatty acid synthesis, in 
Jurkat cells. Under low glucose availability, cells were able to reprogram their metabolism 
to use more fatty acid for ATP production and for survival, only if PHLPP2 was silenced. 
However, the data not rule out the possibility that other AMPK associated pathways could 
also be mediating the metabolic function of PHLPP2.  
In conclusion, the research described in this dissertation makes significant inroads into 
our understanding of the phosphatase PHLPP2, not only in leukemia, but in solid tumors 
as well. These studies provide evidence for a novel miRNA based regulatory mechanism 
for PHLPP2 expression in AML, identify a key energy sensing kinase as a substrate for 
PHLPP2 phosphatase activity and reveal a new role for the PHLPP2 in regulating cell 
survival and death during metabolic stress. 
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Chapter 7 
Materials & Methods 
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Reagents, Chemicals and Antibodies 
All-trans retinoic acid (ATRA) was purchased from Enzo Life Sciences. MG-132 was 
purchased from Calbiochem. BTZ was from LC Laboratories and G418 (Geneticin) was 
purchased from Gibco. The antibody directed against PHLPP1 and PHLPP2 (PHLPPL) 
was purchased from Bethyl Laboratories. Compound C was purchased from Sigma and 
AICAR was purchased from Cell Signaling Technology. Antibodies for Bim, c-myc, E2F1, 
P70S6K, phospho-P70S6K (Thr389), Akt, phospho-Akt (Ser473), ACC, phospho-ACC 
(Ser79), AMPKβ were from Cell Signaling Technology. The antibody for E2F3 was 
purchased from Sigma-Aldrich, Antibodies for C/EBPβ, Noxa, AMPKα, phospho-AMPKα 
(Thr172), and β-Actin were from Santa Cruz Biotechnology. The flow cytometry antibody 
for CD11b was purchased from Biolegend. The antibodies for ULK1 and phospho-ULK1 
(Ser555) were a kind gift from Do-Hyung Kim lab. 
Cell lines, patient cells, cell culture and cell differentiation 
HL-60, U937, THP-1, Jurkat, Molt4, K562, H522 and DLD1 cells were grown in RPMI-
1640, supplemented with 10% FBS, 2 mM L-glutamine and non-essential amino acids. 
Kasumi-1 cells were grown in RPMI-1640 supplemented with 20% FBS and 2 mM L-
glutamine. MV4-11 cells were grown in Iscove’s MDM (Sigma-Aldrich) supplemented with 
10% FBS and 2 mM L-glutamine. KG-1 cells were grown in IMDM supplemented with 20% 
FBS and 2 mM L-glutamine. 293 cells were grown in DMEM with 10% FBS and 2 mM L-
glutamine. All cells were supplemented with 100-units/mL penicillin and 100 ug/mL 
streptomycin and maintained in a humidified atmosphere of 5% CO2 at 37°C.AML patient 
samples were obtained from the Leukemia MDS Tissue Bank of the University of 
Minnesota. The frozen patient samples, highly enriched of leukemic cells, were thawed 
and used for Western blot and microRNA quantification. 
For cell differentiation studies ATRA-treated HL-60 cells were collected and stained with 
CD11b antibody in FACS buffer (2% FBS and 0.1% sodium azide in PBS).  Cells were 
washed twice in FACS buffer and fluorescence was detected using the BD LSR II flow 
cytometer (BD Biosciences). Data were analyzed using FlowJo software. 
mRNA Isolation and RT-PCR 
mRNA was extracted from 1x106 - 5x106 suspension leukemia cells with TRIZOL® 
reagents (Invitrogen) and cDNA was synthesized from 500 ng - 800 ng mRNA template 
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using the DyNAamo cDNA Synthesis Kit (Thermo Scientific), according to manufacturers’ 
protocols. The cDNA was amplified through PCR primers (see Supplemental Information 
for primers). The PCR products were run on a 2% agarose gel, stained with ethidium 
bromide and visualized under UV light.   
microRNA Quantification 
Total miRNAs were extracted from cells using mirVanaTM miRNA isolation kit (Life 
Technologies). cDNA was synthesized by reverse transcription using the miScript II RT kit 
(QIAGEN). Finally, miScript SYBR® Green PCR kit (QIAGEN) was used to quantify the 
levels of individual miRNA in miR-17~92 cluster. The miRNA levels were normalized to an 
U6 internal control. Except for the miR-17~92 cluster measured in leukemia cell lines for 
Figure 2B, which was performed with the MiR-17~92 cluster plate assay kit (Signosis Inc.), 
all measurements of miR-17~92 cluster levels were performed using the miScript® miRNA 
PCR assay (QIAGEN).  
Chromatin Immunoprecipitation Assay 
Chromatin immunoprecipitation was performed using the Millipore ChIP Assay Kit 
according to the manufacturer’s protocol. Briefly, 37% formaldehyde-cross-linked HL-60 
cells were collected, lysed, sonicated to approximately 500bp segments and subjected to 
immunoprecipitation with RNA polymerase II, C/EBPβ antibodies or IgG control antibody 
(Santa Cruz). Immunocomplexes were collected on protein A/G agarose beads blocked 
with salmon sperm DNA and eluted. Cross-links were reversed by incubating at 65°C 
overnight. PCR was performed to amplify different portions of the miR-17~92 promoter 
(primer sequences are in Supplemental Information). PCR products were run on a 2% 
agarose gel, stained with ethidium bromide and visualized under UV light.  For 
quantification of fold enrichment in Pol II or C/EBPβ binding, 5ng of total chromatin was 
used as control and quantitative real time PCR was performed using SYBR Green. 
Western Blotting 
For Western blotting, cells were lysed in RIPA buffer (50 mMTris-HCl (pH 7.5), 150 
mMNaCl, 0.5% v/v sodium deoxycholate, 1% v/v Nonidet P-40, 0.1% SDS) supplemented 
with protease and phosphatase inhibitor cocktails. Lysates were resolved by SDS-PAGE 
and transferred to nitrocellulose membrane. The blots were incubated with specific 
antibodies and chemiluminescent reactions were carried out using the ECL Plus kit 
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(Amersham). Blots were stripped for reuse by washing for 30 min in TBS-T buffer (pH 2.5–
3.0). 
Protein Immunoprecipitation 
For immunoprecipitation, cells were lysed in Buffer A (100 mM HEPES; 0.15 mM MgCl2; 
100 mM KCl; 0.5% IGEPAL) supplemented with protease and phosphatase inhibitor 
cocktails (Calbiochem). Cell lysates were incubated with 1-5μg/ml of antibody at 4°C 
overnight and complexes were captured with protein G Agarose beads (Invitrogen). For 
the immunoprecipitation of the Flag-tagged protein, anti-Flag M2 affinity gel (Sigma) were 
added to the cell lysates directly and incubated at 4°C for 2 hours. Immunoprecipitates 
were resolved by SDS-PAGE and transferred to nitrocellulose membrane. The blots were 
incubated with specific antibodies and chemiluminescent reactions were carried out using 
the ECL Plus kit (Amersham). 
In-vitro Phosphatase Assay 
PHLPP2 protein was immunoprecipitated from the cell lysates according to the protein 
immunoprecipitation method. 2x phosphatase buffer (0.1M Tris-HCL PH7.4; 2mM DTT; 
10mM MnCl2), 25ng AMPKα1β1γ2 recombinant protein (ThermoFisher) were added to 
the immunoprecipitates. The in-vitro phosphatase assay was conducted at 30°C for 15min 
and 2 x Sample buffer (without 2-Mercaptoethanol) was added to stop the reaction. The 
levels of phospho-AMPK α1 and total AMPK protein in the phosphatase reaction products 
were analyzed through Western Blotting.  
Plasmid Constructs 
The PHLPP2 3’ UTR region was amplified using high fidelity Taq polymerase from 
genomic DNA of AML patient leukemia cells using DNeasy® Blood & Tissue Kit (QIAGEN). 
The primers used were: forward 5’GAGCTCGGATCCGAAACAGCACCAGGACAGC3’; 
reverse 5’GAGCTCGCGGCCGCGTTTGTTCTCACTTATCTTC3’. PCR products were 
cloned into the control vector (CV) pcDNA3.1(+) using BamH1/ Not1. DNA sequencing of 
the 3’UTR was carried out by Sanger sequencing and no mutations were found. Briefly, 
the miR-17~92 shRNA plasmid was generated by inserting three individual shRNAs into 
the TripZ vector. The sequences of the shRNAs are:  
shRNA1: AATAAGATGTAACTCATACAATGTGCTTGTATGAGTTACATCTTATTAA;  
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shRNA2: TAAATGAGAACTAATTTTGGATGTGCTTCAAAATTAGTTCTCATTTATT;  
shRNA3: TTATACTGCCAAATCTGACACTGTGCTTGTCAGATTTGGCAGTATAAAT. 
Cell Transfection 
Transfections of PHLPP2 3’UTR constructs into U937 or HL-60 cells, and transfection of 
PHLPP2 full length construct or truncated constructs into Jurkat cells were performed 
using a BioRad Electroporator as described previously (51) or through the NeonTM 
Transfection System (Invitrogen) using the manufacturers protocol. FuGENE® 
Transfection Reagent (Roche) was used for HEK293 cell transfections according to the 
manufacturer’s protocol. Negative control siRNA, C/EBPβ siRNAs, PHLPP1 siRNA, 
PHLPP2 siRNA (GE Dharmacon) and siRNA for c-myc, E2F1, E2F3, (Santa Cruz 
Biotechnology) were introduced into HL-60, U937 or Jurkat cells using the Neon System. 
Cell Death Assay  
For cell viability studies, cells were collected under indicated conditions, washed once with 
cold PBS and stained with Annexin V-FITC and Propidium iodide (PI). The flow cytometry 
data were analyzed using FlowJo software (Tree Star, Inc). 
Seahorse Extracellular Flux Assay 
Seahorse base medium (Agilent, Santa Clara, CA USA) was supplemented with 10mM 
glucose, 1mM sodium pyruvate and 4mM L-glutamine and adjusted to pH 7.4 with 2Mm 
NaOH. Cells were plated at 200,000 cells per well and adhered to the Seahorse 96 well 
culture plate using CellTak (Corning, Oneonta, NY USA).  Extracellular acidification rate 
(ECAR) and oxygen consumption rate (OCR) were measured using the Seahorse XFe96 
(Agilent, Santa Clara, CA USA). 
Fatty Acid Oxidation Assay 
The oxidation of fatty acids was measured by a modified method with the XF Cell Mito 
Stress Test (Agilent). 24 hours prior to the Seahorse assay, replace growth medium with 
substrate-limited medium (0.5 mM glucose, 1 mM GlutaMAX, 0.5 mM carnitine and 1% 
FBS). 45 min prior to the assay, wash the cells once with FAO assay medium (111 mM 
NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 2 mM MgSO4, 1.2 mM NaH2PO4. 2.5 mM glucose, 
0.5 mM carnitine and 5 mM HEPES, PH 7.4). Cells were plated at 200,000 cells per well 
and adhered to the Seahorse 96 well culture plate using CellTak (Corning, Oneonta, NY 
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USA) and incubated in a non-CO2 incubator for 30-45 min at 37°C. Load the assay 
cartridge with XF Cell Mito Stress Test compounds (final concentration: 2.5 μg/ml 
oligomycin, 2 μM FCCP, 2 μM rotenone/4 μM antimycin A). 15 min prior to starting the 
assay, add Eto (final concentration: 40 μM) or vehicle to each well. And incubate for 15 
min at 37 °C in a non-CO2 incubator. Insert the XF Cell Culture Microplate into the XF96 
Analyzer and run the XF Cell Mito Stress Test to measure oxygen consumption rate (OCR). 
The OCR level that was decreased due to the Eto treatment would indicate the level of  
fatty acid oxidation. 
Metabolic labeling experiments in cell culture 
Live, healthy cells were recovered by Ficoll density gradient centrifugation within 24 hours 
prior to experiment.  At 10E6 cells per sample were pelleted and washed in 
glucose/glutamine free medium. For glucose labeling experiments, cells were 
resuspended at 1E6 cells/ml in complete glucose free medium supplemented with 10% 
dialyzed FBS, NEAA, and 4mM L-glutamine for 1 hour. After starvation, cells were 
supplemented with 10mM [1,2-13C] labeled glucose for 24 hours. Cells were then pelleted 
and washed once with cold PBS. Pellets were then resuspended in 100-200μl -20°C 
methanol, snap frozen and stored at -80C. Liquid chromatography/mass spectrometry 
(LC/MS) and gas chromatography/mass spectrometry (GC/MS) were used for 
identification and quantification of labeled metabolites of all samples. [1,2-13C] glucose 
was purchased from Cambridge Isotopes (Tewksbury, MA USA). 
RT-PCR Primer Sequences 
Chromatin Immunoprecipitation Primers 
DNA was amplified with the following primer sets:  
Amplicon 1(~ -1050 binding site): forward 5’GCTGCTGATCATAATCAAGTAT3’,  
Reverse 5’ AGAATACACTTACCCATTCCA3’;  
Amplicon 2 (~ -600 binding site): forward 5’TGGAATGGGTAAGTGTATTCT3’,  
Reverse 5’ TTATCAGTCAATTGTAGCAGAAC3’;  
Amplicon 3 (none binding site): forward 5’CTTGTCCGTATTTACGTTGA3’,  
Reverse 5’ CAGACTCACCAGGAGGAGTA3’. 
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Statistics 
All averages are presented as mean ±SE. Student’s two-tailed test were used for all 
analyses: *P ＜0.05; **P ＜0.01; ***P＜ 0.001. 
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